RESEARCH ARTICLE

Open Access

Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials



Chia-Wen Hsieh^{1,2†}, Chiehfeng Chen^{3,4,5,6†}, Hui-Chuan Su^{1,2} and Kee-Hsin Chen^{1,2,4,7*}

Abstract

Background: Inhaled hypertonic saline (HS) has shown benefit in decreasing airway edema in acute bronchiolitis which is the most common lower respiratory infection resulting in dyspnea among infants under 2 years old. The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of HS in the implementation of treatment with nebulized HS among children with bronchiolitis.

Methods: A systematic literature search was conducted using Cochrane Library, PubMed, EMBASE and Airiti Library (Chinese Database) for randomized controlled trials from inception to July 2019. We calculated pooled risk ratios (RR), mean difference (MD) and 95% CI using RevMan 5.3 for meta-analysis.

Results: There were 4186 children from 32 publications included. Compared to the control group, the HS group exhibited significant reduction of severity of respiratory distress, included studies used the Clinical Severity Score (n = 8; MD, -0.71; 95% Cl, -1.15 to -0.27; $l^2 = 73\%$) and full stop after Respiratory Distress Assessment Instrument (n = 5; MD, -0.60; 95% Cl, -0.95 to -0.26; $l^2 = 0\%$) for evaluation respectively. Further, the HS group decreased the length of hospital stay 0.54 days (n = 20; MD, -0.54; 95% Cl, -0.86 to -0.23; $l^2 = 81\%$).

Conclusions: We conclude that nebulization with 3% saline solution is effective in decreasing the length of hospital stay and the severity of symptoms as compared with 0.9% saline solution among children with acute bronchiolitis. Further rigorous randomized controlled trials with large sample size are needed.

Keywords: Bronchiolitis, Children, Hypertonic saline, Nebulizer treatment, Length of hospital stay, Efficacy

Background

Bronchiolitis is the most common lower-respiratory infection in infants, affecting 68.8% of infants and neonates aged < 12 months [1, 2], and is a major cause of hospitalization in children during the first year of life [3, 4]. Bronchiolitis is

Full list of author information is available at the end of the article



primarily caused by viral infection which results in inflammation of the bronchioles in the lungs [5, 6]. The infection can last $2 \sim 3$ weeks, and causes mucosal congestion and sputum secretion during the disease course [7, 8]. Common symptoms include excessive coughing with tachypnea, fever and wheezing [1, 9].

In case of severe nasal congestion, a child might resort to open-mouth breathing and prone to dyspnea caused by tracheal obstruction, which may cause respiratory failure in severe cases [10, 11]. Infants may be prone to vomit due to frequent coughing at night that affect their

© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: keehsin@gmail.com

[†]Chiehfeng Chen is the author contributed equally to the first author.

¹Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

²Center for Nursing and Healthcare Research in Clinical Practice Application, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

sleeping quality, day time activities and mental status as well as recovery of the body's immune system [12-15].

Approximately 50–80% of bronchiolitis are caused by respiratory syncytial virus (RSV), thereby, treatment by antibiotics is usually ineffective [16]. According to the 2014 American Academy of Pediatrics Bronchiolitis guideline, the primary treatment method is supportive, such as rest, maintain nutrition intake and fluid supplementation [17, 18]. For symptoms such as cough and fever, the use of supportive medications such as antitussive syrup, antipyretics or nebulizer can help relieve the symptoms [18–20].

With the use of normal saline as the diluent in nebulizers and the oxygen as vaporizer, the water molecules or drugs can be breathed through the mouth or nose and spread to the respiratory tract and lungs by the airflow. After the alveolar capillaries absorb the molecules, the drugs can dilute the secretions in the respiratory tract, then induce expectoration and relieve symptoms of bronchospasm [21, 22].

Recently, several studies pointed out that hypertonic saline (3%) is beneficial in inducing the penetration of water molecules into the lung mucosa, allowing the bronchial mucosa or submucosal layers to absorb water molecules and reduce the possibility of edema of the airway [23, 24]. It also uses the principle of vaporization to moisturize the airway surface, increase mucosa cilia function, and accelerate elimination of obstructive sputum to achieve better treatment effects [25]. However, other studies also pointed out that there is no significant difference in efficacy between hypertonic saline and normal saline nebulizers for treating children with bronchiolitis [26–28]. A systematic literature review and meta-analysis by Zhang et al. [29] demonstrated that the use of hypertonic saline can significantly shorten the length of hospital stay, but the article did not provide an explanation for the high heterogeneous results.

The purpose of this study is to conduct a systematic review and meta-analysis of the latest randomized controlled trials (RCTs) to update the effectiveness and safety of using hypertonic saline (3%) for nebulizing treatment in children with bronchiolitis, and we included results of a children's sleep index in the analysis, with the aim to provide a reference for clinical treatment.

Methods

Database searches

We found Mesh terms and related synonyms through the PubMed Mesh Database and used Boolean logic to search for literatures. Keywords and searching strategy were as follows: "bronchiolitis" OR "pediatrics" OR "child*" AND "3% saline" OR "hypertonic saline" AND "saline solution" OR "0.9% saline" OR "normal solution." The study screened the following online databases: Cochrane, PubMed, EMBASE, and Airiti Library. The search period was any publications before July 2019. Only publications in English and Chinese were included. Additionally, we manually searched the literatures cited in related systematic literature reviews and RCTs.

Inclusion criteria

Two independent researchers (CW Hsieh and HC Su) screened the literatures. The inclusion criteria were as follows: (1) population: children aged <18 years with bronchiolitis; (2) intervention: hypertonic saline (3%); (3) control intervention: normal saline (0.9%); (4) results: severity of respiratory distress, length of hospital stay (LOS), rate of hospitalization, rate of readmission, time of sleeping, frequency of waking up in the night, drug side effects, etc.; and (5) study design: RCTs. Exclusion criteria were patients with other comorbidities such as congenital respiratory tract disease, cardiac insufficiency and immunodeficiency. During the screening process of browsing through the titles, abstracts, and full articles, any different opinions that emerged, a third researcher (KH Chen or C Chen) joined the discussion, and a decision was made through consensus opinion.

Literature quality assessment

Two researchers (CW Hsieh and HC Su) used the Cochrane risk of bias tool (RoB) 2.0 to independently conduct a literature risk assessment. The five fields for assessment included (1) Bias arising from the randomization process; (2) bias due to deviations from intended interventions; (3) bias due to missing outcome data; (4) bias in measurement of the outcome; and (5) bias in selection of the reported result. The assessment results were rated as low, some concern, and high risk of bias. According to suggestions by the Cochrane handbook for systematic reviews of interventions, if any one of the fields in the result indices were assessed as having high risk of bias, then the overall assessment of the study would be labeled as high risk.

Next, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used for assessing the evidence body of the included metaanalytical results. Trials included by this study were randomized controlled trials; therefore, the preliminary assessment for evidence level was high, and the assessment was graded based on five downgrade factors, which included risk of bias, inconsistency, indirectness, imprecision, and publication bias. The final quality of evidence was graded as either a high, moderate, low, or very low level. Finally, clinical recommendations were formed according to factors such as the strength of the evidence, clearness of intervention pros and cons, patient preference, and resources, and the recommendation strength was graded as either strong or weak.

Data analysis

Two researchers (CW Hsieh and HC Su) independently extracted research data and conducted a meta-analysis using the Revman 5.3 software (The Nordic Cochrane Centre, Copenhagen, Denmark, 2014). Mean and standard deviation (SD) values were extracted for continuous data, and number of people in each group and number of incidences were extracted to analyze categorical data. The Cochrane Q and I^2 tests were used to assess heterogeneity. When the Q value showed significant difference (p < 0.1), it was considered heterogeneity existed in the study samples. The I^2 test was used to determine the level of heterogeneity between the study samples, and the final results were collectively portrayed in a forest plot to exhibit the effect size and 95% confidence interval (CI).


Sensitivity analysis

The meta-analysis results were cautiously assessed, and if high heterogeneity was noted among the results, then sensitivity and subgroup analyses were conducted. Subgroups were divided based on factors such as the study's research region, hospitalization, and LOS, and the obtained results were compared with results before subgrouping to confirm the stability of the meta-analytical results.

Results

Literature search results

In total, 1423 articles were found in the databases, and 3 articles were manually searched; 1033 articles remained after 393 duplicate articles were excluded; 859 articles were excluded after the titles and abstract were incompatible with the study; and 174 articles were included for careful examination of the full texts. Finally, 32 RCTs [8, 27, 28, 30–58] along with 31 studies were included in the meta-analysis.



| Table 1 Characteristics of the included trials | of the includ | ed trials | | | | | |
|--|---|-----------------------------------|---|---|---|---|----------------------------------|
| Study | Patients | | Intervention | | Comparison | | Outcome |
| year | | Average age (male %) | 3% H/S | Additional drugs | 0.9% N/S | Additional drugs | |
| Country | | RSV positive rate | | | | | |
| Al-Ansari et al. 2010 [30] [ʔ]Saudi Arabia | < 18 mon Inpatients <i>n</i> = 114 | 3.9 mon (59.1%) No information | 5 mL (<i>n</i> = 58) | + 1.5 mg epinephrine | 5 mL (<i>n</i> = 56) | + 1.5 mg epinephrine | LOS CSS |
| Angoulvant et al. 2017 [31] France | 6 wk. ~ 12 mon ED <i>n</i> = 772 | 3 mon (60.2%) 86.4% | 4 mL (<i>n</i> = 385) | | 4 mL (<i>n</i> = 387) | | RDAI ROH Adverse events |
| Anil et al. 2010 [32] Turkey | 6 wk. ~ 24 mon ED <i>n</i> = 149 | 9.5 mon (64.5%) No information | 1) 4 mL ($n = 39$) 2) 4 mL ($n = 36$) | + 1.5 mg epinephrine + 2.5 mg salbutamol | 1) 4 mL ($n = 38$) 2) 4 mL ($n = 36$) | + 1.5 mg epinephrine + 2.5 mg salbutamol | ROR |
| Everard et al. 2014 [8] UK | < 12 mon Inpatients <i>n</i> = 291 | 3.4 mon (54.5%) 61.5% | 4 mL (<i>n</i> = 142) | + standard care | (n = 149) *Nebulizer use not reported | + standard care | LOS RDAI |
| Flores et al. 2016 [27] Portugal | < 12 mon Inpatients <i>n</i> = 68 | 3.6 mon (52.9%) 85.4% | 3 mL (<i>n</i> = 33) | + 1.25 mg salbutamol | 3 mL ($n = 35$) | + 1.25 mg salbutamol | LOS CSS |
| Florin et al. 2014 [28] USA | 2 ~ 24 mon ED <i>n</i> = 62 | 6.7 mon (45.2%) No information | 4 mL (<i>n</i> = 31) | | 4 mL (n = 31) | | ROH |
| Grewal et al. 2009 [33] Canada | 6 wk. ~ 12 mon ED <i>n</i> = 46 | 5 mon (60.9%) 82.2% | 2.5 mL (<i>n</i> = 23) | + 0.5 mL 2.25% epinephrine | 2.5 mL (<i>n</i> = 23) | + 0.5 mL 2.25% epinephrine | RDAI ROH ROR |
| Hou et al. 2016 [3 4] China | 1 ~ 11 mon Inpatients <i>n</i> = 34 | 6 M (50.4%) No information | (<i>n</i> = 17) *how many milliliters not reported | + 1.25 ml atrovent + 1 ml budesonide | (<i>n</i> = 17) *how many milliliters not reported | + 1.25 ml atrovent + 1 ml budesonide | LOS TOS FOWITN |
| lpek et al.2011 [35] Turkey | < 24 mon ED <i>n</i> = 120 | 7.9 mon (59.2%) No information | 1) 4 mL ($n = 30$) 2) 4 mL ($n = 30$) | + 0.15 mg/kg salbutamol | 1) 4 mL ($n = 30$) 2) 4 mL ($n = 30$) | + 0.15 mg/kg salbutamol | ROH |
| Islam et al. 2018 [36] Bangladesh | 1 ~ 24 mon Inpatients <i>n</i> = 90 | 5.4 mon (56.6%) No information | 4 mL ($n = 45$) | | 4 mL (n = 45) | | LOS CSS |
| Kanjanapradap et al. 2018 [37] Thailand | 6 mon~ 5 years Inpatients n = 47 | 20.1 man (60%) 25.5% | 3.5 mL (<i>n</i> = 22) | + 2.5 mg salbutamol | 3.5 mL ($n = 25$) | + 2.5 mg salbutamol | |
| Khanal et al. 2015 [38] Nepal | 6 wk. ~ 24 mon ED/OPD <i>n</i> = 100 | 9.7 M (48%) No information | 4 mL (<i>n</i> = 50) | + 1.5 mg epinephrine | 4 mL ($n = 50$) | + 1.5 mg epinephrine | ROR |

| Study | Patients | | Intervention | | Comparison | | Outcome |
|--|--|--|-------------------------|-----------------------------|-----------------------|-----------------------------|-------------|
| year | | Average age (male %) | 3% H/S | Additional drugs | 0.9% N/S | Additional drugs | |
| Country | | RSV positive rate | | | | | |
| Kose et al. 2016 [39] Turkey | 1 ~ 24 mon Inpatients <i>n</i> = 70 | 7.6 mon (40.3%) No information | 2.5 mL (<i>n</i> = 35) | + 0.15 mg/kg salbutamol | 2.5 mL ($n = 35$) | + 0.15 mg/kg salbutamol | LOS |
| Kuzik et al. 2007 [40] Canada | < 18 mon Inpatients n = 91 | 4.7 mon (59.4%) 68.5% | 4 mL ($n = 45$) | | 4 mL ($n = 46$) | | ros |
| Kuzik et al. 2010 [41] Canada | < 24 mon ED <i>n</i> = 88 | 8.9 mon (77.5%) 47% History of asthma | 4 mL ($n = 44$) | + 1 mg salbutamol | 4 mL ($n = 44$) | + 1 mg salbutamol | RDAI ROH |
| Li et al. 2014 [42] China | 2 ~ 18 mon OPD <i>n</i> = 84 | 7.2 mon (73.3%) No information | 2 mL (<i>n</i> = 42) | | 2 mL ($n = 42$) | | CSS |
| Luo et al. 2010 [44] China | < 24 mon Inpatients <i>n</i> = 93 | 5.8 mon (60.2%) 69.9% | 4 mL ($n = 50$) | + 2.5 mg salbutamol | 4 mL ($n = 43$) | + 2.5 mg salbutamol | LOS |
| Luo et al. 2011 [43] China | < 24 mon Inpatients <i>n</i> = 112 | 5.9 mon (56.3%) 73.2% | 4 mL (n = 57) | | 4 mL ($n = 55$) | | LOS CSS |
| Mahesh Kumar et al. 2013 [45] India | < 24 mon Inpatients <i>n</i> = 40 | 5.9 mon (62.5%) No information | 3 mL (<i>n</i> = 20) | + 0.15 mg/kg albuterol | 3 mL (<i>n</i> = 20) | + 0.15 mg/kg albuterol | ros |
| Mandelberg et al. 2003 [46] Israel | < 12 mon Inpatients <i>n</i> = 52 | 2.9 mon (57.7%) 86.5% | 4 mL (n = 27) | + 1.5 mg epinephrine | 4 mL (n = 25) | + 1.5 mg epinephrine | LOS |
| Miraglia et al. 2012 [47] Italy | < 24 mon Inpatients <i>n</i> = 106 | 4.5 mon (65.1%) 82% | 4 mL (n = 52) | + 1.5 mg epinephrine | 4 mL (n = 54) | + 1.5 mg epinephrine | LOS CSS |
| Morikawa et al. 2018 [48] Japan | < 12 mon Inpatients <i>n</i> = 128 | 4.3 mon (39.2%) No information | 2 mL (<i>n</i> = 63) | + 0.5% 0.1 mL salbutamol | 2 mL ($n = 65$) | + 0.5% 0.1 mL salbutamol | ros |
| Ojha et al. 2014 [49] Nepal | 6 wk. ~ 24 mon Inpatients <i>n</i> = 59 | 8.5 mon (74%) No information | 4 mL ($n = 28$) | | 4 mL ($n = 31$) | | LOS |
| Pandit et al. 2013 [50] India | $2 \sim 12 \mod n$ Inpatients n = 100 | Not reported (Not reported) No information | 4 mL (n = 51) | + 1 mL adrenaline | 4 mL (n = 49) | + 1 mL adrenaline | ros |
| Ratajczyk-Pekrul et al. 2016 [51] Poland | < 18 mon Inpatients <i>n</i> = 78 | 4.9 mon (58.9%) 53.5% | 3 mL (<i>n</i> = 41) | + 0.15 mg/kg salbutamol | 3 mL (<i>n</i> = 37) | + 0.15 mg/kg salbutamol | ros |

| Table 1 Characteristics of the included trials (Continued) | of the include | ed trials (Continued) | | | | | |
|--|---|---|------------------------|--|------------------------|--|----------------------|
| Study | Patients | | Intervention | | Comparison | | Outcome |
| year | | Average age (male %) | 3% H/S | Additional drugs | 0.9% N/S | Additional drugs | |
| Country | | RSV positive rate | | | | | |
| Sarrell et al. 2002 [52] Israel | < 24 mon OPD <i>n</i> = 65 | 12.5 mon (59%) 80% | 2 mL (n = 33) | + 5 mg terbutaline | 2 mL (<i>n</i> = 32) | + 5 mg terbutaline | ROH |
| Sharma et al. 2013 [53] India | 1 ~ 24 mon Inpatients <i>n</i> = 248 | 8.5 mon (76.2%) No information | 4 mL (<i>n</i> = 125) | + 2.5 mg salbutamol | 4 mL (<i>n</i> = 123) | + 2.5 mg salbutamol | ros |
| Silver et al. 2015 [5 4] USA | < 12 mon Inpatients <i>n</i> = 190 | 4.2 mon (61%) 67.5% History of asthma | 4 mL ($n = 93$) | | 4 mL (<i>n</i> = 97) | | ROR |
| Tal et al. 2006 [55] Israel | < 24 mon Inpatients <i>n</i> = 41 | 2.6 mon (56.1%) 80.5% | 4 mL (n = 21) | + 1.5 mg epinephrine | 4 mL ($n = 20$) | + 1.5 mg epinephrine | LOS |
| Teunissen et al. 2014 [56] The Netherlands | < 24 mon Inpatients <i>n</i> = 164 | 3.4 mon (57.1%) 86.2% | 4 mL ($n = 84$) | + 2.5 mg salbutamol | 4 mL (<i>n</i> = 80) | + 2.5 mg salbutamol | ros |
| Wang et al. 2014 [57] China | $2 \sim 14 \text{ mon}$ Inpatients n = 76 | 5.8 mon (56.6%) No information | 2 mL (<i>n</i> = 37) | + 0.5 ml salbutamol + 0.5 mg budesonide | 2 mL (<i>n</i> = 39) | + 0.5 ml salbutamol + 0.5 mg budesonide | LOS TOS FOWITN |
| Wu et al. 2014 [58] USA | < 24 mon ED <i>n</i> = 408 | 6.5 mon (56.8%) 62.4% | 4 mL (n = 211) | | 4 mL ($n = 197$) | | RDAI ROH |
| 1. ED, emergency department; OPD, outpatient department; | t; OPD, outpatie | 1. ED, emergency department; OPD, outpatient department; RSV, respiratory syncytial virus | ry syncytial virus | | | | |

ED, emergency department: OPD, outpatient department: RSV, respiratory syncytial virus
3% HS, 3% hypertonic saline; 0.9% NS, 0.9% normal saline
Epinephrine: Adrenaline; Atrovent, Salbutamol, Albuterol, Terbutaline: Bronchodilator; Budesonide: Corticosteroids
CSS, clinical severity score; RDAI, respiratory distress assessment instrument; LOS, length of hospital stay; ROH, rate of hospitalization; ROR, rate of re-admission; TOS, time of sleeping; FOWITN, frequency of waking up in the night

Details of the search and screening process of articles and reasons for exclusion are presented in Fig. 1.

Characteristics of included studies

Of the 32 selected RCTs, 20 (62.5%) were conducted in the Asian region, and six (18.8%) were conducted in the Americas or European countries. Regarding the research setting, 22 (68.8%) studies were conducted in hospital wards with study targets being hospitalized children, and 10 studies (31.3%) were conducted in emergency wards of outpatient departments. All 4186 included subjects were diagnosed with acute bronchiolitis, 70.5% of subjects had RSV infection, two had a past history of asthma, 2100 (50.2%) were treated with hypertonic saline (3%), and 2086 (49.8%) were treated with normal saline. The mean age of the two population groups were 6.3 months vs. 6.5 months, the sex ratio were 58.3% males vs. 41.7% females, and there were no significant differences regarding the age or sex between these two groups (p > 0.05). Dosages of saline used for nebulizing treatment differed according to each study's design, and the dosage used ranged $2 \sim 5$ ml.




Fig. 2 Risk of bias assessment for the included studies

Table 2 Summary of findings using GRADE

Summary of findings:

3% Hypertonic Saline compared to 0.9% Normal Saline for ped bronchitis

Patient or population: ped bronchitis

Intervention: 3% Hypertonic Saline Setting:

Comparison: 0.9% Normal Saline

| Outcomes | Anticipated absolute effects * (95% CI) | | Relative | N ^e of participants | Certainty of the | Comments |
|---|--|--|--|--------------------------------|-----------------------------------|----------|
| | Risk with 0.9% Normal Saline | Risk with 3% Hypertonic Saline | effect(95% Cl) | (studies) | evidence(GRADE) | |
| CSS | The mean CSS was –3.57 to 8.8 point | MD 0.93 point lower(1.23 lower to 0.62 lower) | I | 2010(11 RCTs) | ⊕⊕coLOW ^{a,b} | |
| RDAI | The mean RDAI was –4.7 to 5.32 point | MD 0.6 point lower(0.95 lower to 0.26 lower) | I | 1369(5 RCTs) | @@@ OMODERATE ^a | |
| ros | The mean LOS was 1.4 to 7.49 days | MD 0.54 days lower(0.86 lower to 0.23 lower) | I | 2055(20 RCTs) | ⊕⊕coLOW ^{a,b} | |
| Rate of hospitalisation | 402 per 1000 | 342 per 1000(298 to 394) | RR 0.85 (0.74 to 1710(8 RCTs) 0.98) | 1710(8 RCTs) | ODERATE ^a | |
| Rate of re-admission | 135 per 1000 | 97 per 1000(53 to 180) | RR 0.72 (0.39 to 1.33) | 485(4 RCTs) | @@@ OMODERATE ^a | |
| Time of sleeping | The mean time of sleeping was 4.54 to 7.32 h | MD 1.72 h higher(0.43 lower to 3.88 higher) | I | 110(2 RCTs) | ⊕⊕coLOW ^{a,b} | |
| Frequency of wake-up in the night | The mean frequency of wake-up in the night was 3.11 to 9.28 time | MD 5.61 time lower(6.54 lower to 4.67 lower) | I | 110(2 RCTs) | @@@ OMODERATE ^a | |
| *The risk in the intervention (Cl: Confidence interval; MD: A | "The risk in the intervention group (and its 95% confidence interval) is based on the ass. CI: Confidence interval: MD: Mean difference; RR: Risk ratio | is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% C) | the relative effect of t | the intervention (and its | : 95% CI) | |

GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect is likely to be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Explanations

a. The overall of Risk of Bias was some concern b. $\rm l^2 > 75\%$ (statistically significant)

| | 20/ | 110 | | 0.0 | | | | Maan Difference | Maan Difference |
|---|-------------|-------------|-----------|------------|-------------|----------------------|---------------|--|--|
| Study or Subaroup | 3% Mean | SD SD | Total | Mean | 9% NS SD | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV. Random. 95% Cl |
| 1.1.1 <1 day | mean | 30 | Total | mean | 30 | Total | TACINIT | rv, Ranuolli, 95% Cl | |
| Anil 2010 - a | 2.9 | 1.2 | 39 | 3.1 | 0.9 | 38 | 4.5% | -0.20 [-0.67, 0.27] | |
| Anil 2010 -b | 3.2 | 1 | 36 | 2.6 | 1.2 | 36 | 4.4% | 0.60 [0.09, 1.11] | |
| Khanal 2015 Subtotal (95% CI) | -3.57 1 | 1.41 | 50 125 | -2.26 | 1.15 | 50 124 | 4.4% 13.2% | -1.31 [-1.81, -0.81] -0.30 [-1.37, 0.76] | |
| Heterogeneity: Tau ² = | = 0.82; Chi | = 27 | .53. df | = 2 (P < | < 0.000 | 001); I ^z | = 93% | | |
| Test for overall effect: | | | • | | | | | | |
| 1.1.2 1-2 day | | | | | | | | | |
| Al-Ansari 2010 | 3.88 1 | 1.13 | 58 | 3.97 | 1.4 | 56 | 4.5% | -0.09 [-0.56, 0.38] | |
| Flores 2016 | 5.8 | 2.1 | 33 | 6.3 | 1.7 | 35 | 3.4% | -0.50 [-1.41, 0.41] | |
| Kose 2016 | 4.4 | 1.2 | 35 | 4.6 | 1.7 | 35 | 4.0% | -0.20 [-0.89, 0.49] | |
| Luo 2010 | 3.4 | 1.2 | 50 | 4.9 | 1.7 | 43 | 4.2% | -1.50 [-2.11, -0.89] | |
| Luo 2011 | | 1.5 | 57 | 7.3 | 1.7 | 55 | 4.2% | -1.60 [-2.19, -1.01] | |
| Mandelberg 2003 | 7.7 1 | | 27 | | 1.49 | 25 | 3.6% | -0.11 [-0.93, 0.71] | |
| Miraglia 2012 | - | 1.3 | 52 | 8.8 | 1.6 | 54 | 4.3% | -0.80 [-1.35, -0.25] | |
| Tal 2006 Subtotal (95% CI) | 6.25 | 1.1 | 21 333 | 7 | 1 | 20 323 | 4.1% 32.2% | -0.75 [-1.39, -0.11] -0.71 [-1.15, -0.27] | • |
| Heterogeneity: Tau ² = Test for overall effect: | | | | = 7 (P = | = 0.000 | 04); I² = | 73% | | |
| 1.1.3 2-3 day | | | | | | | | | |
| Al-Ansari 2010 | 3.85 1 | | 58 | 4.12 | | 56 | 4.6% | -0.27 [-0.69, 0.15] | |
| Flores 2016 | 5.9 | 2.3 | 33 | 6.8 | 2.4 | 34 | 3.0% | -0.90 [-2.03, 0.23] | |
| Luo 2010 | | 1.1 | 50 | 3.8 | 1.5 | 43 | 4.3% | -1.60 [-2.14, -1.06] | |
| Luo 2011 | | 1.1 | 57 | 5.9 | 1.5 | 55 | 4.4% | -2.40 [-2.89, -1.91] | |
| Mandelberg 2003 | | 1.4 | 24 | 6.92 | | 25 | 3.6% | -0.51 [-1.36, 0.34] | |
| Miraglia 2012 | 6.8 | 1.4 | 52 | 8.2 | 1.7 | 54 | 4.2% | -1.40 [-1.99, -0.81] | |
| Tal 2006 Subtotal (95% CI) | 5.35 | 1.3 | 20 294 | 6.45 | 1 | 20 287 | 3.9% 27.9% | -1.10 [-1.82, -0.38] -1.19 [-1.84, -0.54] | |
| Heterogeneity: Tau ² = | - 0 66: Chi | 2 - 17 | | - 6 /D / | . 0 000 | | | -1.19 [-1.04, -0.04] | |
| Test for overall effect: | | | | - 0 (F \$ | · 0.000 | ,101),1 | - 07 70 | | |
| 1.1.4 >3 day | | | | | | | | | |
| Flores 2016 | | 3.2 | 29 | 5.6 | 2.7 | 31 | 2.2% | -0.10 [-1.60, 1.40] | |
| Islam 2018 | 1.64 (| | 45 | - | 1.48 | 45 | 4.4% | -1.36 [-1.88, -0.84] | |
| Luo 2010 | 1.5 | 0.5 | 45 | 2.9 | 0.7 | 40 | 4.8% | -1.40 [-1.66, -1.14] | |
| Luo 2011 | 2.4 | 0.9 | 57 | 4.1 | 1.1 | 55 | 4.6% | -1.70 [-2.07, -1.33] | |
| Mandelberg 2003 | 5.81 1 | | 21 | | 2.03 | 23 | 3.0% | -0.27 [-1.37, 0.83] | |
| Miraglia 2012 | | 1.4 | 52 | 7.6 | 1.6 | 54 | 4.2% | -1.80 [-2.37, -1.23] | |
| Tal 2006 Subtotal (95% CI) | | 1.5 | 13 262 | 5.72 | 1 | 14 262 | 3.3% 26.6% | -1.02 [-1.99, -0.05] -1.38 [-1.68, -1.07] | • |
| Heterogeneity: Tau ² = Test for overall effect: | | | | | = 0.07) | ; ² = 49 | 3% | | |
| Total (95% CI) | | | 1014 | | | 996 | 100.0% | -0.93 [-1.23, -0.62] | ◆ |
| Heterogeneity: Tau ² = | : 0.48: Chi | | | lf = 24 (| P < 0.0 | | | | |
| Test for overall effect: Test for subgroup dif | Z = 5.99 (| P < 0. | .00001 |) | | | | | -4 -2 0 2 4 Favours [3% Hypertonic Saline] Favours [0.9% Normal Saline] |
| Test for subbroad on | ELECTRES 1 | cm== | - 6 43 | ui = .5 (b | - 11 11 | 41 [-= | 14 3 30 | | |
| g. 3 Forest plot o | f the clir | hical | sever | ity sco | re (C | 55) | | | |

Regarding required treatments according to different clinical symptoms, 22 studies (68.8%) combined treatment with epinephrine, bronchodilators, or steroids. The basic characteristics of the included studies are summarized in Table 1.

Quality assessment of the included literature

According to the Cochrane risk of bias tool 2.0, quality assessment results of the included literature showed the following results: (1) For bias arising from the randomization process, 20 (62.5%) studies used the






Fig. 4 Forest plot of the Respiratory Distress Assessment Instrument (RDAI)

| 21.1 America Varik 2007 2.6 1.9 45 3.5 2.9 46 4.0% -0.90 [1.91, 0.11] Varik 2007 2.6 1.9 45 3.5 2.9 46 4.0% -0.90 [1.91, 0.11] Veterageneity: Not applicable Est for overall effect Z = 1.75 (P = 0.08) 2.1.2 2.1.2 1.9 5.1% 0.06 [-0.62, 0.74] Vererad 2016 4.9 2.4 33 4.7 2.3 35 3.6% 0.20 [0.92, 1.32] Staticzyk-Pekrul 2016 3.00 1.81 4.11 1.83 7 4.9% -0.05 [0.77, 0.67] Feunissen 2014 3.03 1.95 84 2.47 1.6 80 5.5% 0.56 [0.02, 1.10] Subtotal (95% CI) 3.00 2.12 1.9 3.00 19.1% 0.25 [-0.10, 0.60] Veterogeneity: Tau"= 0.00; Ch"= 2.22, df = 3 (P = 0.53); P = 0% 7 6.8 5.5% -0.68 [-1.12, -0.26] Sose 2016 3.08 2.11 3.05 3.22 2.26 3.5 3.9% -0.12 [-1.7, 0.93] Wiraglia 2012 4.9 1.3 5.2 | | 39 | %HS | | 0. | 9% N S | | | Mean Difference | Mean Difference |
|--|---------------------------------|--------------------------------|---------|-------|----------|-----------------------|--------|---------|----------------------|---|
| $ \frac{2}{4} \frac{1}{4} \frac{2}{2} \frac{1}{4} 1$ | Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Subtotal (95% C) 45 $\frac{46}{2}$ 4.0% $\frac{16}{2}$ | 2.1.1 America | | | | | | | | | |
| Test for overall effect $Z = 1.75$ (P = 0.08) 21.2 Europe Everard 2014 3.76 3.05 142 3.7 2.82 149 5.1% 0.06 [-0.62, 0.74] Toires 2016 4.9 2.4 33 4.7 2.3 35 3.6% 0.20 [-0.92, 1.32] Tatajczyc/Pekrul 2016 3.06 1.61 41 3.11 16.8 37 4.9% -0.05 [-0.77, 0.67] Everard 2014 3.03 1.95 84 2.47 1.6 80 5.5% 0.05 [-0.77, 0.67] Everard 2014 3.03 1.95 84 2.47 1.6 80 5.5% 0.05 [-0.70, 0.60] Heterogenety. Tau ² = 0.00; Ch ² = 2.22, df = 3 (P = 0.53); P = 0% Test for overall effect $Z = 3.42$ (P = 0.16) 2.1.4 Asia (exclude China) W-Ansar12010 1.4 141 58 1.88 1.76 56 5.4% -0.48 [-107, 0.11] Subtotal (95% CI) 2.02 45 3.11 1.13 45 5.9% -0.69 [-1.12, -0.26] Goes 2016 3.08 2.11 35 3.2 2.35 35 3.8% -0.12 [-1.17, 0.93] Mandelsh Kumar 2013 2.42 0.99 2.02 2.88 1.76 2.02 4.4% -0.36 [-1.42, -0.28] Mandelsh Kumar 2013 2.12 50 49 2.02 2.88 1.76 2.02 4.4% -0.03 [-1.42, -0.13] Writegila 2012 4.9 1.3 52 5.5 1.8 65 4.9% 0.20 [-0.55, 0.95] Official 3.92 2.17 2.51 4.00 1.9 4.9 5.0% -0.01 [-0.27, 0.11 25, 0.16] Morikawa 2018 4.81 2.14 63 4.61 2.18 65 4.9% 0.20 [-0.55, 0.95] Official 3.92 2.17 2.51 4.00 1.9 4.9 5.0% -0.16 [-0.67, 0.56] Shathotal (95% CI) 5.12 5.17 2.02 1.41% -0.00 [-1.87, 0.06] Heterogenety. Tau ² = 0.08 (-Fi = 10 (-P = 0.04); P = 48% Test for overall effect $Z = 2.81$ (P = 0.050); P = 0% Test for overall effect $Z = 2.81$ (P = 0.050); P = 0% Test for overall effect $Z = 3.02$ (Chi ² = 10 (P < 0.0001); P = 0.86 Test for overall effect $Z = 3.02$ (Chi ² = 10 (P (< 0.00001); P = 8)% Test for overall effect $Z = 3.02$ (Chi ² = 10 (P (< 0.00001); P = 8)% Test for overall effect $Z = 3.02$ (Chi ² = 10 (P (< 0.00001); P = 8)% Test for overall effect $Z = 3.02$ (Chi ² = 10.00001); P = 0.80 Test for overall effect $Z = 3.02$ (Chi ² = 10.00001); P = 0.80 Test for overall effect $Z = 3.02$ (Chi ² = 10.00001); P = 0.00001; P = | Kuzik 2007 Subtotal (95% CI) | 2.6 | 1.9 | | 3.5 | 2.9 | | | | |
| 2.1.2 Europe Everad 2014 3.76 3.05 142 3.7 2.82 149 5.1% 0.06 [0.62, 0.74] Fibre 2016 4.9 2.4 33 4.7 2.3 35 3.6% 0.20 [0.92, 1.32] Ratajczyk-Petrul 2018 3.06 1.61 41 3.11 163 3.7 4.9% -0.05 [0.07, 1.0] Subtotal (95°C) 300 2.01 19.1% 0.25 [0.10, 0.60] 2.4.4 Asia (exclude China) V-Ancarl 2010 1.4 1.41 58 1.88 1.76 56 5.4% -0.48 [-1.07, 0.11] silam 2010 1.4 1.41 58 1.88 1.76 56 5.4% -0.48 [-1.07, 0.11] silam 2010 1.4 1.41 58 1.88 1.76 56 5.4% -0.48 [-1.07, 0.11] silam 2010 2.42 0.92 45 3.11 113 45 5.9% -0.58 [-1.12, 0.26] cose 2016 3.08 2.11 3.3 2.2 3.5 3.5 3.8% -0.12 [-1.17, 0.93] Wahesh Kumar 2013 2.25 0.88 2.0 2.88 1.76 20 4.4% -0.03 [-1.49, 0.23] Wahesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% -0.03 [-1.49, 0.23] Winabelierg 2003 3.12 2.7 4 1.9 2.5 4.4% -0.01 [-1.07, -0.13] Winabelierg 2013 4.12 1.4 63 4.61 2.18 6.6 4.8% -0.01 [-0.25, 0.15] Morkawa 2014 1.37 0.96 2.8 1.52 1.18 31 5.5% -0.06 [-0.50, 0.60] Pandit 2013 3.92 1.72 51 4.08 1.9 4.9 5.0% -0.16 [-0.87, 0.55] Shama 2013 2.26 0.98 1.25 2.66 0.93 1.23 6.4% -0.01 [-0.25, 0.23] Farama 2013 2.26 0.98 1.25 2.55 5.23 55.3% -0.36 [-0.61, -0.11] Heterogenety: Tau ² = 0.08; Ch ² = 19,18, df = 10 (P = 0.04); P = 43% Test tor versall effect. Z = 2.81 (P = 0.005) 2.1.5 China Hou 2010 6 1.2 50 7.4 1.5 4.3 55% -1.40 [-1.96, 0.84] Luo 2011 4.8 1.2 57 6.4 1.14 55 5.7% -1.26 [-1.81, -0.61] Luo 2010 6 1.2 50 7.4 1.5 4.27, 85.7% -1.26 [-1.82, -1.25] Heterogenety: Tau ² = 0.08; Ch ² = 1.98, df = 19 (P = 0.0000)) 2.1.5 China Heterogenety: Tau ² = 0.08; Ch ² = 1.98, df = 19 (P = 0.00001); P = 81% Test tor versall effect. Z = 2.81 (P = 0.00001) 2.1.5 China Heterogenety: Tau ² = 0.38; Ch ² = 1.9 (P = 0.00001); P = 81% Test tor versall effect. Z = 3.09 (P = 0.00001) Total (95% Ch) 1031 1024 100.0% -0.54 [0.86, -0.23] Heterogenety: Tau ² = 0.08; Ch ² = 1.99, df = 19 (P = 0.00001); P = 81% Test tor versall effect. Z = 3.00 (P = 0.00001) Total (95% Ch) 1031 1024 100.0% -0.54 [0.86, -0.23] Heterogenety: Tau ² = 0.08; Ch ² = 0.00007) | Heterogeneity: Not appli | cable | | | | | | | | |
| Secard 2014 3.76 3.05 142 3.7 2.82 149 5.1% 0.66 [-0.62, 0.74] Tores 2016 4.9 2.4 33 4.7 2.8 5 3.6% 0.20 [-0.92, 1.32] tradiagx/e Perful 2016 3.06 161 41 3.11 1.63 3.7 4.9% -0.06 [-0.7, 0.67] teunisen 2014 3.03 1.95 84 2.47 1.6 80 5.5% 0.56 [0.02, 1.10] tabitotal (95% C) 300 30 11 91.1% 0.25 [-0.10, 0.60] telerogeneity. Tau ² = 0.00; Chi ² = 2.22, df = 3 ($P = 0.53$); $P = 0\%$ test for overall effect Z = 3.142 ($P = 0.16$) telerogeneity. Tau ² = 0.02; Chi ² = 1.13 35 7.28 5.5% -0.48 [1.07, 0.11] tabitotal (95% C) 2.6 1.4 2.12 5.6 1.6 54 5.5% -0.48 [1.07, 0.11] telerogeneity. Tau ² = 0.02; Chi ² = 1.18, df = 10 ($P = 0.04$); $P = 0\%$ test for overall effect Z = 3.19 1.13 5.5 5.5% -0.68 [-1.12, -0.26] toose 2016 3.06 2.11 35 3.22 3.5 3.8% -0.68 [-1.12, -0.26] toose 2016 3.06 2.11 35 3.22 3.5 3.8% -0.68 [-1.12, -0.26] tabitotal (95% C) 2.6 1.4 2.11 8.5 4.4% -0.63 [-1.49, 0.23] tabitotal (95% C) 5.6 1.6 5.4 5.5% -0.70 [-1.25, -0.15] tool 1.20 2.6 1.4 2.1 3.5 1.7 20 4.1% -0.00 [-0.87, 0.55] tabitotal (95% C) 5.08 125 2.56 5.23 5.5% -0.36 [0.61, -0.11] telerogeneity. Tau ² = 0.08; Chi ² = 10.16, df = 10 ($P = 0.04$); $P = 48\%$ test for overall effect Z = 2.81 ($P = 0.005$) 1.5 China tau 2016 4.38 0.91 17 5.65 1.02 17 5.2% -1.26 [1.81, -0.61] tabitotal (95% C) 10 10 1 15 2.5 5 7.4 1.5 13 5.5% 1.40 [-1.96, -0.84] tau 2016 4.38 0.91 17 5.65 1.02 17 5.2% -1.26 [1.81, -0.61] telerogeneity. Tau ² = 0.08; Chi ² = 10.8, df = 10 ($P = 0.000$); $P = 0\%$ test for overall effect Z = 3.28 ($P = 0.0000$) telerogeneity. Tau ² = 0.08; Chi ² = 10.8, df = 10 ($P = 0.00001$); $P = 1\%$ test for overall effect Z = 3.09 ($P = 0.56$); $P = 0\%$ test for overall effect Z = 3.09 ($P = 0.00001$) Total (95% C) 10 1031 1024 100.0% -0.54 [-0.86, -0.23] telerogeneity. Tau ² = 0.36; Chi ² = 10.98; df = 10 ($P = 0.00001$); $P = 1\%$ test for overall effect Z = 3.00 ($P = 0.00001$) Total (95% C) 10 1031 1024 100.0% -0.54 [-0.86, -0.23] telerogeneity. Tau ² = 0.06; Chi ² = 20.00001 Total (95% C) 10 1 | est for overall effect: Z = | = 1.75 (P | = 0.08 |) | | | | | | |
| Signard 2014 3.76 3.05 142 3.7 2.82 149 5.1% 0.06 ($b20, 0.74$) Tores 2016 4.9 2.4 33 4.7 2.8 36% 0.20 ($b22, 1.32$) Teunisen 2014 3.03 1.95 84 2.47 1.6 80 5.5% 0.56 ($b02, 1.10$) Subtal (95% C(1) 300 31 19.1% 0.55 ($b.74$ 0.56 ($b.02, 1.10$) Subtal (95% C(1) 300 31 19.1% 0.56 ($b.14$ 1.11 1.63 37 4.9% 0.56 ($b02, 1.10$) Subtal ($b.16$ 41 3.11 1.63 37 4.9% 0.56 ($b02, 1.10$) Subtal ($b.16\%$ C(1) 300 31 19.1% 0.55 ($b.16$ 0.56 ($b.2\%$) Teunisen 2014 2.22 ($d=3$ ($P=0.53$); $P=0\%$ Test for overall effect Z = 1.42 ($P=0.16$) 2.14 Asia (exclude China) V-Ansari 2010 1.4 1.41 56 1.88 1.76 56 5.4% 0.48 ($1.07, 0.11$] Simo 2016 2.42 0.92 45 3.11 1.13 45 5.9% 0.68 ($1.12, 0.26$] So es 2016 3.08 2.11 35 3.22 35 3.8% 0.070 ($1.25, 0.15$] Simo 2018 2.42 0.92 2.45 3.11 1.13 45 5.5% 0.70 ($1.12, 0.05$] Simo 2018 4.81 2.14 63 4.61 2.18 65 4.8% 0.70 ($1.12, 0.05$] Simo 2018 4.81 2.14 63 4.61 2.18 65 4.8% 0.70 ($1.03, 0.05$] Subtal (95% C(1) 525 5.23 55.5% 0.716 ($1.05, 0.55$] Simo 2016 2.6 1.4 21 3.5 1.7 20 4.1% 0.005 ($1.05, 0.55$] Simo 2011 4.87 1.2 65 1.02 17 5.2% 0.00 ($1.05, 0.55$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.00 ($1.05, 0.55$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.00 ($1.05, 0.55$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.00 ($1.05, 0.55$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.00 ($1.05, 0.55$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.00 ($1.05, 0.55$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.33 0.91 17 5.65 1.02 17 5.2% 0.12 ($1.10, 0.56$] Simo 2016 4.12 5.00 7.4 1.5 5 5.7\% 1.60 ($2.08, 1.12$] Simo 201 | 4.0.5 | | | | | | | | | |
| There 2016 4.9 2.4 33 4.7 2.3 35 3.6% 0.20 [0.92 , 1.32] Ratajczyk-Pekru 2016 3.06 1.61 41 3.11 1.63 37 4.9% -0.05 [0.70 , 0.67] rearbor 2014 3.03 1.95 84 2.47 1.6 80 55% Leterospenety: Trai ² = 0.00; Ch ² = 2.22, df = 3 (P = 0.53); P ² = 0% Test for overall effect Z = 1.42 (P = 0.16) 2.1.4 Asia (exclude China) V-Ansari 2010 2.42 0.92 45 3.11 1.13 45 5.9% -0.48 [-1.07 , 0.11] slam 2010 2.42 0.92 45 3.11 1.13 45 5.9% -0.69 [-1.12 , -0.26] Cose 2016 3.08 2.11 35 3.2 2.35 35 3.8% -0.12 [-1.17 , 0.93] dandelseng 2003 3 1.2 27 4 1.9 25 4.4% -0.06 [-1.12 , -0.26] Cose 2016 3.08 2.11 35 3.2 2.35 5.36% -0.02 [-1.18 , -0.33 [-1.49 , 0.23] dandelseng 2003 3 1.2 27 4 1.9 25 4.4% -0.01 [-1.87 , -0.13] dandelseng 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [-0.87 , 0.55] Pharma 2013 2.26 0.98 1.25 2.86 0.93 1.23 0.4% -0.01 [-0.25 , 0.51] bharma 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [-0.87 , 0.55] charma 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [-0.87 , 0.55] Subtotal (95% CI) 5.25 5.23 55.3% -0.38 [-0.64 , -0.11] deterogenety: Trai ² = 0.08 (ch ² = 1.91.6, df = 10 (P = 0.04); P = 48% Test for overall effect Z = 3.81 (P = 0.00001) Total (95% CI) 101 1031 1024 100.0% -0.54 [-0.84] Luc 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.82 , -1.26 [-1.81 , -0.84] Luc 2011 4.8 1.2 67 6.4 1.4 55 5.7% -1.60 [-2.08 , -1.24] Subtotal (95% CI) 101 1031 1024 100.0% -0.54 [-0.84] Luc 2010 6 1.2 2.98, df = 3 (P = 0.00001) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86 , -0.23] deterogenetity: Tau ² = 0.03; Ch ² = 101.89, df = 19 (P < 0.00011); P = 81% Test for overall effect Z = 3.90; Ch ² = 10.199, df = 19 (P < 0.00011); P = 81% Test for overall effect Z = 3.90; Ch ² = 10.039, df = 19 (P < 0.00011); P = 81% Test for overall effect Z = 3.90; Ch ² = 10.039, df = 19 (P < 0.00001) Total (95% CI) 101 1031 1024 100.0% -0.54 [-0.54 [-0.86 , -0.23] -2 -2 -2 -2 -2 -2 -2 -2 | • | 0.70 | 0.05 | | | | | 5.4.00 | | |
| Table zyk-Pekrul 2016 3.06 1.61 41 3.11 1.63 37 4.9% -0.05 [-0.77, 0.87] Teunisera 2014 3.03 1.95 84 2.47 1.6 80 6.5% 0.056 [0.02, 1.10] Subtotal (95% CI) 300 301 19.1% 0.25 [-0.10, 0.60] Telerogeneity. Tau ² = 0.00; Ch ² = 2.22, df = 3 (P = 0.53); P = 0% Test to roverall effect Z = 14.2 (P = 0.16) 2.1.4 Asia (exclude China) W-Ansari 2010 1.4 1.41 158 1.88 1.76 56 5.4% -0.48 [-1.07, 0.11] Sear 2018 2.42 0.92 45 3.11 1.13 45 5.9% -0.69 [-1.12, -0.26] Soese 2016 3.08 2.11 35 2.2.25 5 3.3% -0.12 [-1.17, 0.93] Mahesh Kurmar 2013 2.25 0.89 120 2.88 1.76 20 4.4% -0.83 [-1.49, -0.23] Maneberg 2003 3 1.2 27 4 1.9 25 4.4% -0.10 [-1.87, -0.13] Miraglia 2012 4.9 1.3 52 5.6 1.6 54 5.5% -0.07 [-1.25, -0.15] Miraglia 2012 4.9 1.3 52 5.6 1.6 54 5.5% -0.07 [-1.25, -0.15] Miraglia 2012 4.9 1.3 52 5.6 1.0 3.13 2.3 6.4% -0.015 [-0.50, 0.60] Pandt 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [-0.87, 0.55] Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% -0.09 [-1.86, 0.06] Subtotal (95% CI) 525 5.55% -0.36 [-0.61, -0.11] Heterogeneity. Tau ² = 0.08; Ch ² = 1.9.16, df = 10 (P = 0.04); P = 48% Test tor overall effect Z = 3.89 (P = 0.0005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.61] Juo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [1.96, -0.84] Juo 2010 6 1.2 50 7.4 1.4 59 5.5% -1.40 [1.96, -0.84] Juo 2010 6 1.2 62 1.38 37 7.49 1.41 39 5.5% -1.40 [-1.96, -0.24] Heterogeneity. Tau ² = 0.03; Ch ² = 10.189, df = 19 (P < 0.0001); P = 81% Test tor overall effect Z = 3.90; Ch ² = 10.189, df = 19 (P < 0.0001); P = 81% Test tor overall effect Z = 3.90; Ch ² = 0.00050 Total (95% CI) 101 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity. Tau ² = 0.03; Ch ² = 10.189, df = 19 (P < 0.00001); P = 81% Test tor overall effect Z = 3.90; P = 0.00007) Total (95% CI) 101 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity. Tau ² = 0.03; Ch ² = 10.039, df = 19 (P < 0.00001); P = 81% Test tor overall effect Z = 3.90; P = 0.00007) | | | | | | | | | | |
| Teurissen 2014 3.03 1.95 94 2.47 1.6 80 5.5% 0.66 [0.02, 1.10] Subtotal (95% CI) 300 301 19.1% 0.25 [-0.10, 0.60] tetersogeneity: Tau ² = 0.00, Ch ² = 2.22, df = 3 (P = 0.53); P = 0% Test for overall effect Z = 1.42 (P = 0.16) 21.4 Abase (acclude China) W-Ansari 2010 1.4 1.41 58 1.88 1.76 56 5.4% -0.48 [-1.07, 0.11] sharpest Kumar 2013 2.45 0.89 2.02 2.88 1.76 20 4.4% -0.68 [-1.07, 0.13] Atandelberg 2003 3 1.2 27 4 1.9 25 4.4% -0.63 [-1.40, 0.23] Atandelberg 2003 3 1.2 27 4 1.9 25 4.4% -0.63 [-1.40, 0.23] Atandelberg 2003 3 1.2 27 4 1.9 25 4.4% -0.63 [-1.40, 0.23] Atandelberg 2003 3 1.2 27 4 1.9 25 4.4% -0.63 [-1.60, 0.55] Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% -0.01 [-0.25, 0.25] Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% -0.01 [-0.25, 0.25] Sharma 2013 2.65 0.98 125 2.56 0.93 123 6.4% -0.01 [-0.25, 0.25] Sharma 2013 2.65 0.98 125 2.56 0.93 123 6.4% -0.01 [-0.25, 0.25] Sharma 2013 2.65 0.98 125 2.56 1.02 17 5.2% -1.26 [-1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.34] Test for overall effect Z = 2.81 (P = 0.005); P = 0% Test for overall effect Z = 2.08, Ch ² = 10.18, df = 10 (P = 0.04); P = 48% Test for overall effect Z = 2.08, Ch ² = 10.19, df = 19 (P < 0.00001); P = 0% Test for overall effect Z = 2.08, Ch ² = 10.19, df = 19 (P < 0.00001); P = 0% Test for overall effect Z = 2.08, Ch ² = 10.98, df = 19 (P < 0.00001); P = 0% Test for overall effect Z = 2.39, CP = 0.00001 Total (95% CI) 101 1024 100.0% -0.54 [-0.86, -0.23] Test for overall effect Z = 2.39, CP = 0.00001 Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Test for overall effect Z = 3.90; CP = 0.00001; P = 0% Test for overall effect Z = 3.90; CP = 0.00001; P = 0% Test for overall effect Z = 3.90; CP = 0.00001; P = 0% Test for overall effect Z = 2.39; CP = 0.00001; P = 0.00001; P = 0.0000; P = 0.00001; P = 0.0000; P = 0. | | | | | | | | | | |
| Subtotal (95% CI) 300 301 19.1% 0.25 [-0.10, 0.60] Heterogeneity: Tau ² = 0.00; Ch ² = 2.22, df = 3 (P = 0.53); P = 0% rest for overall effect Z = 1.42 (P = 0.16) 21.4 Asia (exclude China) W-Ansari 2010 1.4 1.41 58 1.88 1.76 56 5.4% -0.48 [-1.07, 0.11] slam 2018 2.42 0.92 45 3.11 1.13 45 5.9% -0.68 [-1.12, -0.26] cose 2016 3.08 2.11 35 1.2 2.73 45 3.2 35 3.8% -0.12 [-1.17, 0.93] tahesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% -0.63 [-1.49, 0.23] tahesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% -0.63 [-1.49, 0.23] tahesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% -0.07 [-1.25, 0.15] tofnikawa 2018 4.81 2.14 63 4.61 2.18 65 4.8% 0.07 [0-1.25, 0.15] tofnikawa 2018 4.81 2.14 63 4.81 2.18 65 4.8% 0.02 [-0.55, 0.66] thana 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [-0.87, 0.55] tharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% -0.01 [-0.25, 0.23] theterogeneity: Tau ² = 0.08; Ch ² = 19.16, df = 10 (P = 0.04); P = 48% rest for overall effect Z = 2.81 (P = 0.05); 21.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.81] tota 2016 5.02 1.33 37 7.49 1.41 39 5.2% -1.69 [-1.80, -1.21] teterogeneity: Tau ² = 0.00; Ch ² = 2.08, df = 3 (P = 0.000); P = 0.% rest for overall effect Z = 10.62 (P < 0.00001) rest for overall effect Z = 10.62 (P < 0.00001); P = 81% rest for overall effect Z = 10.62 (P < 0.00001); P = 81% rest for overall effect Z = 3.9 (P = 0.0007) Fauter 25% bit proteopic Salinel Exorut 50 9% bit proteopic Salinel | | | | | | | | | | |
| $ \begin{array}{c} \text{Heterogeneily: Tau^2 = 0.00; Ch^2 = 2.22, df = 3 (P = 0.53); P = 0\% \\ \text{rest for overall effect } Z = 1.42 (P = 0.16) \\ \hline \text{HAssari 2010} & 1.4 & 1.41 & 58 & 1.88 & 1.76 & 56 & 5.4\% & -0.48 [-1.07, 0.11] \\ \text{sim 2018} & 2.42 & 0.92 & 45 & 3.11 & 1.13 & 45 & 5.9\% & -0.69 [-1.12, -0.26] \\ \text{soge 2016} & 3.08 & 2.11 & 35 & 3.2 & 2.35 & 3.8\% & -0.12 [+1.7, 0.93] \\ \text{Hanesh Kumar 2013} & 2.25 & 0.89 & 20 & 2.88 & 1.76 & 20 & 4.4\% & -1.00 [+1.87, -0.13] \\ \text{Hanesh Kumar 2013} & 2.12 & 2.7 & 4 & 1.9 & 2.5 & 4.4\% & -0.05 [+0.57, 0.56] \\ \text{Hanesh Kumar 2013} & 2.12 & 2.7 & 4 & 1.9 & 2.5 & 4.4\% & -0.01 [+0.27, 0.15] \\ \text{Iorikawa 2018} & 4.81 & 2.14 & 63 & 4.61 & 2.18 & 65 & 4.8\% & 0.20 [+0.57, 0.56] \\ \text{Jha 2014} & 1.87 & 0.96 & 28 & 1.82 & 1.18 & 31 & 5.5\% & 0.05 [+0.50, 0.60] \\ \text{Jinha 2013} & 2.65 & 0.98 & 125 & 2.66 & 0.93 & 123 & 6.4\% & -0.01 [+0.27, 0.23] \\ \text{raindi 2013} & 3.26 & 0.98 & 125 & 2.66 & 0.93 & 123 & 6.4\% & -0.01 [+0.27, 0.23] \\ \text{raindi 2013} & 3.26 & 0.98 & 125 & 2.66 & 0.93 & 123 & 6.4\% & -0.01 [+0.27, 0.23] \\ \text{raindi 2013} & 3.26 & 0.98 & 125 & 2.65 & 5.23 & 5.5.\% & -0.36 [-0.61, 0.61] \\ \text{Jubotal (95\% Cl)} & 525 & 523 & 55.3\% & -1.26 [+.91, -0.61] \\ \text{rest for overall effect } Z = 2.81 (P = 0.004); P = 48\% \\ \text{rest for overall effect } Z = 2.08 & (Ch^2 = 0.005); P = 0\% \\ \text{rest for overall effect } Z = 1.062 (P < 0.00001); \\ \text{rotal (95\% Cl)} & 1031 & 1024 & 100.0\% & -0.54 [-0.86, -0.23] \\ \text{rest for overall effect } Z = 1.39; (Ch^2 = 10.19, 6), (f^2 = 10, (P < 0.00001); P = 81\% \\ \text{rest for overall effect } Z = 1.39; (Ch^2 = 10.08, (f^2 = 19 (P < 0.00001); P = 81\% \\ \text{rest for overall effect } Z = 3.39 (P = 0.00007) \\ \end{array}$ | | 3.03 | 1.90 | | 2.47 | 1.0 | | | | ◆ |
| Test for overall effect: $Z = 1.42$ ($P = 0.16$) 2.1.4 Asia (exclude China) W-Ansai 2010 1 4 1.41 58 1.88 1.76 56 5.4% -0.48 [1.07, 0.11] slam 2018 2.42 0.32 45 3.11 1.13 45 5.9% -0.69 [-1.12, -0.26] cose 2016 3.30 2.11 35 3.2 2.35 35 3.8% -0.12 [-1.17, 0.93] dahesh Kumar 2013 2.25 0.99 20 2.88 1.76 20 4.4% -0.63 [-1.87, -0.13] diraglia 2012 4.9 1.3 52 5.6 1.6 54 5.5% -0.70 [-1.25, -0.15] dorikawa 2018 4.81 2.14 63 4.61 2.18 65 4.8% 0.20 [-0.50, 0.50] jha 2014 1.87 0.96 2.8 1.82 1.18 31 5.5% 0.55 (-0.50, 0.60] andi 2013 3.92 1.72 51 4.08 1.9 4.9 5.0% -0.16 [-0.87, 0.55] sharma 2013 3.92 1.72 51 4.08 1.9 4.9 5.0% -0.16 [-0.87, 0.55] sharma 2013 3.92 1.72 5.1 4.08 1.9 4.9 5.0% -0.16 [-0.87, 0.55] sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% -0.01 [-0.25, 0.21] reterogeneity. Tau ² = 0.06; ChF ² = 1.91, 6, df = 10 ($P = 0.04$); $P = 48\%$ Test for overall effect: $Z = 2.81$ ($P = 0.005$) 2.1.5 China Hou 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.26 [-1.91, -0.61] uo 2010 6 1.2 50 7.4 1.5 42 1.30 5.7% -1.60 [-2.08, -1.12] Vang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 101 1024 100.0% -0.54 [-0.86, -0.23] +tetrogeneity. Tau ² = 0.03; ChF ² = 10.19.8, df = 19 ($P < 0.00001$); $P = 81\%$ Fest for overall effect: $Z = 3.90$ ($P = 0.0001$) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] +tetrogeneity. Tau ² = 0.39; ChF ² = 101.98, df = 19 ($P < 0.00001$); $P = 81\%$ Fest for overall effect: $Z = 3.90$ ($P = 0.0007$) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] +tetrogeneity. Tau ² = 0.39; ChF ² = 101.98, df = 19 ($P < 0.00001$); $P = 81\%$ Fest for overall effect: $Z = 3.90$ | | 00 [.] Chi ²∍ | = 2 22 | | (P = 0.5 | (3): I ² = | | | 0.20 [0.10, 0.00] | - |
| 2.1.4 Asia (exclude China) N-Ansari 2010 1.4 1.41 58 1.88 1.76 56 5.4% -0.48 [1.07, 0.11] slam 2018 2.42 0.92 45 3.11 1.13 45 5.9% -0.68 [1.12, -0.93] dvanesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% -0.68 [1.12, -0.93] dvanesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% -0.68 [1.48, 0.23] dvandelberg 2003 3 1.2 27 4 1.9 25 4.4% -1.00 [1.87, -0.13] dvandelberg 2003 3 1.2 27 4 1.9 25 4.4% -0.68 [1.42, 0.23] dvandelberg 2014 4.87 0.96 28 1.82 1.18 51 5.5% 0.05 [0.05, 0.95] Oha 2014 1.87 0.96 28 1.82 1.18 31 5.5% 0.05 [0.05, 0.05] Pandit 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [-0.87, 0.56] Sharma 2013 2.65 0.98 1.25 2.66 0.93 123 6.4% -0.00 [1.08, 0.06] Subtotal (95% CI) 525 523 55.3% -0.36 [0.61, -0.11] Heterogeneibt; Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); P = 48% Test for overall effect Z = 2.81 (P = 0.005) 2.1.5 China Hou 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.26 [1.91, -0.61] Luo 2011 6 1.2 50 7.4 1.5 43 5.5% -0.36 [0.68, -0.23] Heterogeneibt; Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect Z = 10.62 (P < 0.00001); P = 81% Test for overall effect Z = 10.92 (CH ² = 10.19.8, df = 19 (P < 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.56); P = 0% Test for overall effect Z = 3.39 (P = 0.0001); P = 81% Test for overall effect Z = 3.39 (P = 0.0001); P = 81% Test for overall effect Z = 3.39 (P = 0.0001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 90% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.00001); P = 81% Test for overall effect Z = 3.39 (P = 0.0000 | | | | | () – 0.c | | 0.0 | | | |
| Al-Ansari 2010 1, 4 1, 41 58 1, 88 1, 76 56 54% -0.48 [-1.07, 0, 11] slam 2018 2, 42 0, 92 45 3, 11 1, 13 45 5, 9% -0.68 [-1, 12, 0, 26] (xose 2016 3, 08 2, 11 35 3, 2, 2, 5 35 3, 88% -0.12 [-1, 17, 0, 93] Wahesh Kumar 2013 2, 25 0, 89 20 2, 88 1, 76 20 4, 4% -0.63 [-1, 49, 0, 23] Wandelberg 2003 3 1, 2 27 4 1, 9 25 4, 4% -0.63 [-1, 49, 0, 23] Wandelberg 2003 3 1, 2 27 4 1, 9 25 4, 4% -0.01 [-1, 87, -0.13] Wiraglia 2014 1, 87 0, 96 28 1, 82 1, 18 65 4, 8% 0, 20 [-0, 55, 0, 95] Ojha 2014 1, 87 0, 96 28 1, 82 1, 18 31 5, 55% -0.05 [-0, 50, 0, 60] Pandit 2013 2, 65 0, 98 125 2, 66 0, 93 123 6, 4% -0.01 [-0, 25, 0, 23] Fandit 2013 2, 65 0, 98 125 2, 66 0, 93 123 6, 4% -0.01 [-0, 25, 0, 23] Fal 2006 2, 6 1, 4 21 3, 5 1, 7 20 4, 1% -0.90 [-1, 86, 0.06] Subtotal (9% CI) 525 523 5, 55, 3% -0.36 [-0, 61, -0, 11] Heterogeneity: Tau ² = 0.08; Chi ² = 19, 16, df = 10 (P = 0.04); I ² = 48% Test for overall effect Z = 2, 81 (P = 0.005) Z.1,5 China Hou 2016 4, 39 0, 91 17 5, 65 1, 02 17 5, 2% -1, 26 [-1, 91, -0, 61] Luo 2010 6 1, 2 50 7, 4 1, 5 43 5, 5% -1, 40 [-1, 96, -0, 61] Luo 2011 4, 8 1, 2 57 6, 4 1, 4 55 5, 7% -1, 60 [-2, 08, -1, 12] Wang 2014 5, 62 1, 38 37 7, 49 1, 41 39 5, 2% -1, 87 [-2, 50, -1, 24] Wang 2014 5, 62 1, 38 37 7, 49 1, 41 39 5, 2% -1, 87 [-2, 50, -1, 24] Wang 2014 5, 62 1, 38 37 7, 49 1, 41 39 5, 2% -1, 87 [-2, 50, -1, 24] Wang 2014 5, 62 1, 03 (P = 0.0001) Fotal (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0, 03; Chi ² = 10, 19, et ol.00001); I ² = 81% Test for overail effect Z = 3, 39 (P = 0.0007) Fotal (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0, 39; Chi ² = 10 (P < 0.00001); I ² = 81% Test for overail effect Z = 3, 39 (P = 0.0007) | | | | , | | | | | | |
| slam 2018 2.42 0.92 45 3.11 1.13 45 5.9% $-0.69 [1.12, -0.26]$ Gose 2016 3.08 2.11 35 3.2 2.35 35 3.8% $-0.12 [+1.71, 0.03]$ Wahesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% $-0.063 [1.49, 0.23]$ Wandelberg 2003 3 1.2 27 4 1.9 25 4.4% $-1.00 [-1.87, -0.13]$ Winagila 2012 4.9 1.3 52 5.6 1.6 54 5.5% $-0.70 [-1.25, -0.16]$ Workawa 2018 4.81 2.14 63 4.61 2.18 65 4.8% $0.20 [-0.55, 0.95]$ Dha 2014 1.87 0.96 28 1.82 1.18 31 5.5% $0.05 [-0.50, 0.60]$ Pandit 2013 3.92 1.72 51 4.08 1.9 49 5.0% $-0.16 [-0.87, 0.55]$ Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% $-0.01 [-0.25, 0.23]$ Tal 2006 2.6 1.4 21 3.5 1.7 20 4.1% $-0.00 [-1.86, 0.06]$ Subtotal (95% CI) 525 5.23 55.3% $-0.36 [-0.61, -0.11]$ Heterogeneity: Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); P = 48% Test for overall effect: Z = 2.81 (P = 0.005) 2.1.5 China Hou 2010 6 1.2 50 7.4 1.5 43 5.5% $-1.26 [1.91, -0.61]$ Luo 2010 6 1.2 50 7.4 1.5 43 5.5% $-1.54 [-1.82, -1.26]$ Subtotal (95% CI) 161 154 2.1.6% $-1.54 [-1.82, -1.26]$ Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: Z = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: Z = 0.39; Chi ² = 10.198, df = 19 (P < 0.00001); P = 81% Test for overall effect: Z = 0.39; Chi ² = 10.198, df = 19 (P < 0.00001); P = 81% Test for overall effect: Z = 3.39 (P = 0.0007) Favours [0.98; Nummal Saline] | - | na) | | | | | | | | |
| Cose 2016 3.08 2.11 35 3.2 2.35 35 3.8% $-0.12[+1.17, 0.93]$ Wahesh Kumar 2013 2.25 0.89 200 2.88 1.76 20 4.4% $-0.63[+1.49, 0.23]$ Wahesh Kumar 2013 2.25 0.8 1.00 [1.87, -0.13] 1.00 [1.87, -0.13] Wiraglia 2012 4.9 1.3 52 5.6 1.6 5.4 % 0.20 0.55 0.95 Oha 2014 1.87 0.96 2.18 1.55% 0.05 0.50 0.50 Oha 2014 1.87 0.96 2.8 1.82 1.18 3.5% 0.016 0.025 0.23 Oha 2014 1.87 0.96 2.8 0.21 1.80 0.90 1.80 0.06 Pandit 2013 3.92 1.72 51 4.08 1.9 4.9 5.0% -0.05 0.23 1.35 1.72 4.18 1.74 9.09 1.41 0.90 1.80 0.06 0.36 0.06 0.36 0.06 0.36 0.36 0.111 0.35 | | | | | | | 56 | 5.4% | -0.48 [-1.07, 0.11] | |
| Mahesh Kumar 2013 2.25 0.89 20 2.88 1.76 20 4.4% $-0.63[1.49, 0.23]$ Mandelberg 2003 3 1.2 27 4 1.9 25 4.4% $-1.00[1.87, -0.13]$ Wiraglia 2012 4.9 1.3 52 5.6 1.6 54 5.5% $-0.70[1.25, -0.15]$ Dyna 2014 1.87 0.96 28 1.82 1.18 31 5.5% $0.20[0.55, 0.36]$ Dyna 2014 1.87 0.96 28 1.82 1.18 31 5.5% $0.05[0.50, 0.60]$ Pandit 2013 3.92 1.72 51 4.08 1.9 49 5.0% $-0.16[0.87, 0.55]$ Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% $-0.00[10.25, 0.23]$ Fal 2006 2.6 1.4 21 3.5 1.7 20 4.1% $-0.90[1.86, 0.06]$ Eator overall effect: Z = 2.81 (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% $-1.26[1.91, -0.61]$ Luo 2010 6 1.2 50 7.4 1.5 43 5.5% $-1.40[1.86, -0.84]$ Luo 2010 6 1.2 50 7.4 1.5 43 5.5% $-1.87[2.50, -1.24]$ Subtotal (95% CI) 161 17 9 (P < 0.00001); P = 81% Test for overall effect: Z = 0.05; Chi ² = 10.68, df = 19 (P < 0.00001); P = 81% Test for overall effect: Z = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); P = 81% Test for overall effect: Z = 3.39 (P = 0.0007) Total (95% CI) 0 1031 1024 100.0% $-0.54[-0.86, -0.23]$ Heterogeneity: Tau ² = 0.09; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: Z = 3.39 (P = 0.0007) Total (95% CI) 0 1031 1024 100.0% $-0.54[-0.86, -0.23]$ Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); P = 81% Test for overall effect: Z = 3.39 (P = 0.0007) | | | | | | | 45 | 5.9% | -0.69 [-1.12, -0.26] | |
| Mandelberg 2003 3 1.2 27 4 1.9 25 4.4% $-1.00 [-1.87, -0.13]$ Miraglia 2012 4.9 1.3 52 5.6 1.6 54 5.5% $-0.70 [-1.25, -0.15]$ Morikawa 2018 4.81 2.14 63 4.61 2.18 65 4.8% $0.20 [-0.55, 0.95]$ Djha 2014 1.87 0.96 28 1.82 1.18 15 5.5% $0.05 [-0.50, 0.60]$ Pandit 2013 3.92 1.72 51 4.08 1.9 49 5.0% $-0.16 [-0.87, 0.55]$ Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% $-0.01 [-0.25, 0.23]$ Fal 2006 2.6 1.4 21 3.5 1.7 20 4.1% $-0.90 [-1.86, 0.06]$ Subtotal (95% CI) 525 523 55.3% $-0.36 [-0.61, -0.11]$ Heterogeneity: Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); P = 48% Frest for overall effect: Z = 2.81 (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% $-1.26 [-1.91, -0.61]$ Luo 2010 6 1.2 50 7.4 1.5 43 5.5% $-1.80 [-2.08, -1.12]$ Nang 2014 5.62 1.38 37 7.49 1.41 39 5.2% $-1.87 [-2.50, -1.24]$ Subtotal (95% CI) 161 154 21.6% $-1.54 [-1.82, -1.25]$ Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Fest for overall effect: Z = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); P = 81% Fest for overall effect: Z = 3.39 (P = 0.0007) Fotal (95% CI) 1031 1024 100.0% $-0.54 [-0.86, -0.23]$ Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); P = 81% Fest for overall effect: Z = 3.39 (P = 0.0007) | | | | | | | | | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | | | | | | | | |
| Morikawa 2018 4.81 2.14 63 4.61 2.18 65 4.8% 0.20 [-0.56, 0.96] Diha 2014 1.87 0.96 28 1.82 1.18 31 5.5% 0.05 [-0.50, 0.60] Pandit 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.01 [-0.25, 0.23] Fal 2006 2.6 1.4 21 3.5 1.7 20 4.1% -0.90 [-1.86, 0.06] Subtotal (95% CI) 525 523 55.3% -0.36 [-0.61, -0.11] Heterogeneity: Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); P = 48% Fest for overall effect: $Z = 2.81$ (P = 0.005) 2.1.5 China Hou 2010 6 1.2 50 7.4 1.5 43 55.% -1.40 [-1.86, -0.84] Luo 2010 6 1.2 50 7.4 1.5 43 55.% -1.40 [-1.86, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Heterogeneity: Tau ² = 0.00; Chi ² = 108, df = 3 (P = 0.56); P = 0% Fest for overall effect: $Z = 1.062$ (P < 0.00001) Fotal (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.88, df = 19 (P < 0.00001); P = 81% Fest for overall effect $Z = 3.39$ (Ch = 0.007) Fotal (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.88, df = 19 (P < 0.00001); P = 81% Fest for overall effect $Z = 3.39$ (Ch = 0.0007) | - | | | | | | | | | |
| Diha 2014 1.87 0.96 28 1.82 1.18 31 5.5% 0.05 [0.50, 0.60] Pandit 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [0.87, 0.55] Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% -0.01 [0.25, 0.23] Fal 2006 2.6 1.4 21 3.5 1.7 20 4.1% -0.90 [1.86, 0.06] Subtotal (95% CI) 525 523 55.3% -0.36 [-0.61, -0.11] Heterogeneity: Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); P = 48% Test for overall effect: $Z = 2.81$ (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.0, -1.24] Subtotal (95% CI) 161 154 21.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: $Z = 10.62$ (P < 0.00001) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); P = 81% Test for overall effect: $Z = 3.39$ (Ch = 0.007) Favours (3% Hypertonic Saline) Evorums (0.9% Normal Saline) | | | | | | | | | | |
| Pandit 2013 3.92 1.72 51 4.08 1.9 49 5.0% -0.16 [-0.87, 0.55] Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% -0.01 [-0.25, 0.23] Tal 2006 2.6 1.4 21 3.5 1.7 20 4.1% -0.90 [-1.86, 0.06] Subtotal (95% CI) 525 523 55.3% -0.36 [-0.61, -0.11] Heterogeneity: Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); P = 48% Test for overall effect: $Z = 2.81$ (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 2.1.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); I ² = 0% Test for overall effect: Z = 10.62 (P < 0.00001) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.88, df = 19 (P < 0.00001); I ² = 81% Test for overall effect: Z = 3.39 (P = 0.007) | | | | | | | | | | |
| Sharma 2013 2.65 0.98 125 2.66 0.93 123 6.4% $-0.01 [-0.25, 0.23]$ Fal 2006 2.6 1.4 21 3.5 1.7 20 4.1% $-0.90 [-1.86, 0.06]$ Subtotal (95% CI) 525 523 55.3% $-0.36 [-0.61, -0.11]$ Heterogeneity: Tau ² = 0.08; Ch ² = 19.16, df = 10 (P = 0.04); P = 48% Fest for overall effect: Z = 2.81 (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% $-1.26 [-1.91, -0.61]$ Luo 2010 6 1.2 50 7.4 1.5 43 5.5% $-1.40 [-1.96, -0.84]$ Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% $-1.60 [-2.08, -1.12]$ Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% $-1.87 [-2.50, -1.24]$ Subtotal (95% CI) 161 154 21.6% $-1.54 [-1.82, -1.25]$ Heterogeneity: Tau ² = 0.00; Ch ² = 2.08, df = 3 (P = 0.56); P = 0% Fest for overall effect: Z = 10.62 (P < 0.00001); P = 81% Fest for overall effect: Z = 3.39 (Ch ² = 101.88, df = 19 (P < 0.00001); P = 81% Fest for overall effect: Z = 3.39 (P = 0.0007) | -, | | | | | | | | | |
| Tal 2006 2.6 1.4 21 3.5 1.7 20 4.1% $-0.90[-1.86, 0.06]$ Subtotal (95% CI) 525 523 55.3% $-0.36[-0.61, -0.11]$ Heterogeneity: Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); P = 48% Test for overall effect: Z = 2.81 (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% $-1.26[-1.91, -0.61]$ Luo 2010 6 1.2 50 7.4 1.5 43 5.5% $-1.40[-1.96, -0.84]$ Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% $-1.60[-2.08, -1.12]$ Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% $-1.87[-2.50, -1.24]$ Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: Z = 10.62 (P < 0.00001) Fotal (95% CI) 1031 1024 100.0% $-0.54[-0.86, -0.23]$ Heterogeneity: Tau ² = 0.39; Chi ² = 101.88, df = 19 (P < 0.00001); P = 81% Test for overall effect: Z = 3.39 (P = 0.0007) | | | | | | | | | | |
| Subtotal (95% CI) 525 523 55.3% -0.36 [-0.61, -0.11] Heterogeneity: Tau ² = 0.08; Ch ² = 19.16, df = 10 (P = 0.04); P = 48% Test for overall effect: $Z = 2.81$ (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 21.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Ch ² = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: $Z = 10.62$ (P < 0.00001) Fotal (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Ch ² = 101.88, df = 19 (P < 0.00001); P = 81% Test for overall effect: $Z = 3.39$ (CP = 0.0007) Fest for overall effect: $Z = 3.39$ (CP = 0.0007) | | | | | | | | | | |
| Heterogeneity: Tau ² = 0.08; Chi ² = 19.16, df = 10 (P = 0.04); I ² = 48% Fest for overall effect: $Z = 2.81$ (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.67 [-2.50, -1.24] Subtotal (95% Cl) 161 154 2.1.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); I ² = 0% Fest for overall effect: $Z = 10.62$ (P < 0.00001) Fotal (95% Cl) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.88, df = 19 (P < 0.00001); I ² = 81% Fest for overall effect: $Z = 3.39$ (P = 0.0007) | | 2.6 | 1.4 | | 3.5 | 1.7 | | | | |
| Test for overall effect: $Z = 2.81$ (P = 0.005) 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 2.1.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); I ² = 0% Test for overall effect: $Z = 10.62$ (P < 0.00001) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); I ² = 81% Test for overall effect: $Z = 3.39$ (P = 0.0007) Favours 10.9% Normal Saline] | | no- chiz- | - 10 10 | | 0 /P - | 0.045-1 | | | -0.50 [-0.01, -0.11] | • |
| 2.1.5 China Hou 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 21.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% Fest for overall effect Z = 10.62 (P < 0.00001); P = 81% Fest for overall effect Z = 3.39 (P = 0.0007) Fotal (95% CI) - 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.88, df = 19 (P < 0.00001); P = 81% Fest for overall effect Z = 3.39 (P = 0.0007) | | | | | 0 (1 - | 0.04), 1 | - 407 | 0 | | |
| How 2016 4.39 0.91 17 5.65 1.02 17 5.2% -1.26 [-1.91, -0.61] Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96, -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 2.1.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); i ² = 0% Test for overall effect: Z = 10.62 (P < 0.00001) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); i ² = 81% Test for overall effect: Z = 3.39 (P = 0.0007) Favours 10.9% Normal Saline] | | 2.2. (| | -, | | | | | | |
| Luo 2010 6 1.2 50 7.4 1.5 43 5.5% -1.40 [-1.96] -0.84] Luo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 2.1.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); i ² = 0% Fest for overall effect: Z = 10.62 (P < 0.00001) Fotal (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.88, df = 19 (P < 0.00001); i ² = 81% Fest for overall effect: Z = 3.39 (P = 0.0007) Fest for overall effect: Z = 3.39 (P = 0.0007) | 2.1.5 China | | | | | | | | | |
| uo 2011 4.8 1.2 57 6.4 1.4 55 5.7% -1.60 [-2.08, -1.12] Wang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 21.6% -1.54 [-1.82, -1.25] reterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); P = 0% rest for overall effect: Z = 10.62 (P < 0.00001) | Hou 2016 | 4.39 | 0.91 | 17 | 5.65 | 1.02 | 17 | 5.2% | -1.26 [-1.91, -0.61] | |
| Nang 2014 5.62 1.38 37 7.49 1.41 39 5.2% -1.87 [-2.50, -1.24] Subtotal (95% CI) 161 154 21.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); I ² = 0% Test for overall effect: Z = 10.62 (P < 0.00001) | Luo 2010 | 6 | 1.2 | | 7.4 | 1.5 | 43 | 5.5% | -1.40 [-1.96, -0.84] | |
| Subtotal (95% CI) 161 154 21.6% -1.54 [-1.82, -1.25] Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); i ² = 0% Test for overall effect: Z = 10.62 (P < 0.00001) Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); i ² = 81% Test for overall effect: Z = 3.39 (P = 0.0007) Favours (3% Hypertonic Saline] Eavours (0.9% Normal Saline] | Luo 2011 | | | | | | | | | |
| Heterogeneity: Tau ² = 0.00; Chi ² = 2.08, df = 3 (P = 0.56); i ² = 0% Test for overall effect: Z = 10.62 (P < 0.00001) | Wang 2014 | 5.62 | 1.38 | | 7.49 | 1.41 | | | | |
| Test for overall effect: Z = 10.62 (P < 0.00001) | | | | | | | | 21.6% | -1.54 [-1.82, -1.25] | ▼ |
| Total (95% CI) 1031 1024 100.0% -0.54 [-0.86, -0.23] Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); i ² = 81% Test for overall effect: Z = 3.39 (P = 0.0007) Featours [3% Hypertonic Saline] Eavours [0.9% Normal Saline] | | | | | (P = 0.5 | ю); I*= | U% | | | |
| Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); i ² = 81% Test for overall effect: Z = 3.39 (P = 0.0007) Favours (3% Hypertonic Saline) Eavours (0.9% Normal Saline) | i est for overall effect: Z= | = 10.62 (F | - < 0.0 | 0001) | | | | | | |
| Heterogeneity: Tau ² = 0.39; Chi ² = 101.98, df = 19 (P < 0.00001); i ² = 81% Test for overall effect: Z = 3.39 (P = 0.0007) Favours (3% Hypertonic Saline) Eavours (0.9% Normal Saline) | Total (95% CI) | | | 1031 | | | 1024 | 100.0% | -0.54 [-0.86, -0.23] | ◆ |
| Test for overall effect: Z = 3.39 (P = 0.0007) | | 39: Chi≊∍ | | | 19 (P < | : 0 000 | | | | |
| | | | | | | 5.000 | | 5170 | -4 | |
| | | | | | = 3 (P | < 0.00 | 1011_P | = 95.6% | | Favours [3% Hypertonic Saline] Favours [0.9% Normal Saline] |

computer for random grouping and used a light-proof envelope to keep the groups hidden during the process; 11 studies (34.4%) did not clearly explain randomization or hidden process, whereas one study (3.1%) grouped subjects according to the order of admission, which did not meet randomization requirements and was assessed to be with high risk of bias. (2) For bias due to deviations from the intended intervention, both subjects and caretakers in 23 studies (71.9%) were blinded, six studies (18.8%) had no information on whether blinding was performed, and three studies (9.4%) indicated that neither subjects nor caretakers were blinded, and therefore,





these were assessed to be with high risk of bias. (3) For bias due to missing outcome data, 20 studies (62.5%) conformed to the intention-to-treat principle, and although there were certain data losses during the study process, those did not affect the balance of the subjects' basic characteristics, and these were determined to be with low risk of bias; five studies (15.6%) had no information on whether loss of data affected the results, and these were assessed to be with some concern of bias. (4) For bias in measurement of the outcome, research personnel were the ones who measured the severity of respiratory distress, and it was not explained whether the evaluators were blinded. Thus, this could have caused some bias in measurement outcomes, and it was assessed to be with some concern of bias. (5) No situations of bias in selection of the reported results were found in the included articles, and the articles were assessed to be with low risk of bias. Finally, for overall assessment, seven studies (21.9%) showed low risk of bias, 21 studies (65.6%) showed some concern of bias, and four studies (12.5%) showed high risk of bias. Overall assessment result of the literature was some concern of bias, the details of which are demonstrated in Fig. 2.

GRADE was used to assess the evidence body of the included literature. The study included RCTs such that the starting evidence grade was high. However, regarding the severity level of respiratory distress, the evidence level was degraded considering that the overall risk assessment results indicated some concern about bias. With regards to the severity of respiratory distress, the Clinical Severity Score (CSS) was used to assess the severity of respiratory distress, and a forest plot was used to demonstrate the high heterogeneity ($I^2 > 75\%$). Thus, the evidence level was degraded owing to inconsistency. Regarding the LOS, considering that the overall risk assessment results showed bias with some concern and the forest plot also showed high heterogeneity ($I^2 > 75\%$), the evidence level was degraded owing to risk of bias and inconsistency, and the overall evidence level was moderately low, with details summarized in Table 2. Lastly, in accordance with the evidence that the intervention measure could significantly improve the severity of respiratory distress and shorten the LOS while causing no severe adverse effects, results showed that the 3% HS benefits outweighed the risks, and this practice could be strongly recommended.


Meta-analytical results

Primary results: severity of respiratory distress

Regarding the severity of respiratory distress, the included studies used the CSS and Respiratory Distress Assessment Instrument (RDAI) for evaluation.

Clinical severity score (CSS)

In total, 11 studies used the CSS for evaluation. According to differences in days of measurement for each study (ranging $1 \sim 3$ days), four subgroups were used for analysis as follow: < 1 day of measurement (n = 2, participants = 249), 1 or 2 days of measurement (n = 8, participants = 656), 2 or 3 days of measurement (n = 8, participants = 581), and > 3 days of measurement (n = 7, participants = 524). Results showed that compared to the group that used normal saline, the group that used 3% hypertonic saline for nebulizing treatment had



| Study or Subgroup | Mean | % HS SD | Total | Mean | 9% N S SD | | Weight | Mean Difference IV, Random, 95% Cl | Mean Difference IV, Random, 95% Cl |
|-----------------------------------|--------|------------|--------|------|--------------|--------|--------|---------------------------------------|---|
| Hou 2016 | 3.11 | 1.76 | 17 | 8.38 | 2.11 | 17 | 51.3% | -5.27 [-6.58, -3.96] | |
| Vang 2014 | 3.32 | 1.87 | 37 | 9.28 | 3.82 | 39 | 48.7% | -5.96 [-7.30, -4.62] | |
| fotal (95% CI) | | | 54 | | | 56 | 100.0% | -5.61 [-6.54, -4.67] | ◆ |
| leterogeneity: Tau ² = | | | | | 0.47); | ² = 0% | | _ | |
| est for overall effect | Z=11.7 | 4 (P < | 0.0000 | 11) | | | | | Favours [3% Hypertonic Saline] Favours [0.9% Normal Saline] |

significantly greater differences in the score for respiratory distress severity for the subgroups of $1 \sim 2$, $2 \sim 3$, and > 3 days with 0.71 points (n = 8; MD, -0.71; 95% CI, -1.15 to -0.27; $I^2 = 73\%$), 1.19 points (n = 8; MD, -1.19; 95% CI, -1.84 to -0.54; $I^2 = 87\%$), and 1.38 points (n = 7; MD, -1.38; 95% CI, -1.68 to -1.07; $I^2 = 49\%$), respectively. Only the subgroup which had < 1 day of measurement did not show a statistically significant difference between the two test groups (MD, -0.30; 95% CI, -1.37 to 0.76, $I^2 = 93\%$). Data are shown in Fig. 3.

Respiratory distress assessment instrument (RDAI)

In total, five papers used the RDAI for evaluation. There were 1369 subjects in total, and the meta-analytical results showed that compared to the group that used normal saline, those used hypertonic saline for nebulizing treatment had a mean 0.6 points lower score of respiratory distress severity (n = 5; MD, -0.60; 95% CI, -0.95 to -0.26; $I^2 = 0\%$), as demonstrated in Fig. 4.

Secondary results

Length of hospital stay (LOS)

In total, 20 studies were included with 2055 subjects. Meta-analytical results showed that compared to the group using normal saline, the group using hypertonic saline for nebulizing treatment had a 0.54-day shorter LOS (n = 20; MD, -0.54; 95% CI, -0.86 to -0.23; $I^2 = 81\%$), as demonstrated in Fig. 6. Because this result was highly heterogeneous, further subgroup analyses were performed with respect to different regions, which greatly reduced the heterogeneity: the Americas and Europe ($I^2 = 0\%$), Asia (excluding China) ($I^2 = 48\%$), and China ($I^2 = 0\%$), as demonstrated in Fig. 5.

Rate of hospitalization

In total, eight studies were included with 1710 subjects. Meta-analytical results showed that compared to the group using normal saline, the group using hypertonic saline for nebulizing treatment had a significant lower rate of hospitalization (n = 8; RR, 0.85; 95% CI, 0.74 to 0.98; $l^2 = 10\%$), as shown in Fig. 6.

Rate of readmission

In total, four studies were included with 485 subjects. Meta-analytical results showed that compared to the group using normal saline, the group using hypertonic saline for nebulizing treatment had lower rates of readmission (n = 4; RR, 0.72; 95% CI, 0.39 to 1.33; $I^2 = 26\%$), but it did not reach statistical significance, as shown in Fig. 7.

Time of sleeping

Two studies were included with 110 subjects. Metaanalytical results showed that compared to the group using normal saline, the using hypertonic saline for nebulizing treatment had 1.72 h longer sleep time at night (n = 2; MD, 1.72; 95% CI, -0.43 to 3.88; $I^2 = 91\%$), but this did not reach statistical significance, as shown in Fig. 8.

Frequency of waking up in the night

Two studies were included with 110 subjects. Metaanalytical results showed that compared to the group using normal saline, the using hypertonic saline for nebulizing treatment demonstrated effectively reduced the frequency of waking up in the night by five times (n = 2; MD, - 5.61; 95% CI, - 6.54 to - 4.67; $I^2 = 0\%$), as shown in Fig. 9.

Adverse events

Twelve studies reported mild adverse events, including cough [27, 31, 39, 54, 56, 58], bronchospasm [39, 56], vomiting and diarrhea [33, 50], desaturation [56], agitation [40, 56], rhinorrhea [27], tachycardia [57], hoarse voices [43], vigorous crying [40], vomiting and diarrhea [33, 50]. One study [26] reported adverse event (bradycardia and desaturation) in hypertonic saline group. However, these were mild and resolved naturally and all subjects completed the trial process.

Sensitivity analysis results

Because the forest plot for LOS showed high heterogeneity, we conducted a sensitivity analysis regarding this and used research method differences (PICO) for a subgroup analysis based on whether there was combined use of other drugs. The results after grouping showed no significant effects on the overall results. However, when a subgroup analysis was done for different regions (Americas, Europe, China, and other Asian countries), it was found that the heterogeneity greatly decreased, and high heterogeneity existed among groups ($I^2 = 95.6\%$), demonstrating that this may be the cause for the heterogeneity.

Analysis of publication

Because there were more than 10 trials in our systemic review, therefore we created and examined a funnel plot to explore possible publication bias. There appeared to be no evidence of publication bias in the included studies.

Discussion

Results of the meta-analyses in this study showed that compared to the use of normal saline and regardless of whether or not children were hospitalized, the use of hypertonic saline for nebulizing treatment improved the severity of respiratory distress, extended the sleep time, reduced the frequency of waking up during the night, and shortened the children's LOS. For non-hospitalized children, it also reduced the rate of hospitalization.

All subjects included in the trials were diagnosed with acute bronchiolitis, and there were no significant differences in the sex ratio. However, the severity of respiratory syncytial virus (RSV) infection was inconsistent, and this might have affected the effects of the interventions. Additionally, all subjects in the study were children aged < 2 years, and only one study included subjects aged between 6 months and 5 years old. However, the measurement results for respiratory distress severity in that particular study were recorded as median and quartiles and could not be included in data calculations. Therefore, that study was excluded from the meta-analysis. The study only included subjects aged < 2 years for analysis; therefore, additional research will be required to verify whether the study results are suitable for children aged > 2 years.

There were differences in the intervention measures in each of the studies included. The nebulization treatment time lasted for $20 \sim 30$ min, but the saline dosage used for nebulizing ranged from 2 to 5 ml. In addition, for subjects with different clinical symptoms, most studies combined treatment with epinephrine, bronchodilators, or steroids. Although this may have affected the treatment results, it was an unavoidable variable owing to treatment needs. Regarding this, the study conducted subgroup analyses on the aforementioned two variables (saline dosage and drug combinations). It was found that neither of these variables were the cause of the high heterogeneity. Related literature also pointed out that combined drugs were not the primary reasons interfering with the efficacy of results [59–61]. The primary result in this study was respiratory distress severity. Results demonstrated no significant difference in disease improvement for <1 day of nebulizing treatment; however, with a longer duration of nebulizing treatment with hypertonic saline, improvements in respiratory distress severity scores were more significant. We speculated the following two reasons could be the causes for this effect. First, it takes more than 1 day for hypertonic saline to reach its efficacy, after children are hospitalized for treatment, their autoimmunity and body strength recover along with an increase in the treatment duration. Second, the disease severity is gradually ameliorated along with the disease course, thus showing more-significant treatment efficacy [62-64].

The study results showed that those who used hypertonic saline for nebulizing treatment had 0.54 less day of LOS compared to those who used normal saline. It was statistically significant, although the amount of decline is small, and this is a huge breakthrough in hospitals where inpatients are saturated. Longer LOS was observed in the Chinese studies than studies conducted in other countries, might because of different local customs and insurance systems. For example, the hospitalization costs can be fully covered by health insurance among children who diagnosed with bronchiolitis. Therefore, caregivers may decide to discharge from hospital until children completely recovered. National cultural differences may be another factor [29, 42–44], but this would require further research for verification.

Sleep quality is relatively important for children's mental and physical development [13–15]. This is the first study to analyze sleep quality (including sleep time and frequency of waking up at night) in children with bronchiolitis undergoing nebulizing treatment. Among the five studies of Chinese subjects included, only two investigated night-time sleep quality [34, 57]. In these two articles, it was stated that the sleep time and frequency of waking up at night (opening eyes as the calculation standard) were recorded by the nurse and family member from 8 pm to the next day 8 am. Results showed that hypertonic saline was effective in reducing the frequency of waking up at night. Although the results did not reach significance, it was a major breakthrough regarding investigation of sleep quality. We suggest that in the future clinical trials, it should include sleep quality as an index of measurements.

Limitations

The study had three main limitations: (1) inconsistent disease severity in the included subjects; (2) differences between studies with respect to dosage of hypertonic saline used for the intervention and the combined use of drugs such as bronchodilators; and (3) evaluators of the severity of respiratory distress were either medical

personnel or research personnel who were not blinded. All these factors may have affected the quality of the study results.

Conclusions

Using hypertonic saline for nebulizing treatment in children with bronchiolitis can significantly improve the severity of respiratory distress, shorten the LOS, and increase the children's night-time sleep quality. It is recommended that a large-scale randomized clinical trial with a standardized design be conducted in the future to investigate the effects of hypertonic saline in children with bronchiolitis.

Abbreviations

ED: emergency department; OPD: outpatient department; RSV: respiratory syncytial virus; 3% HS: 3% hypertonic saline; 0.9% NS: 0.9% normal saline; CSS: clinical severity score; RDAI: respiratory distress assessment instrument; LOS: length of hospital stay; ROH: rate of hospitalization; ROR: rate of readmission; TOS: time of sleeping; FOWITN: frequency of waking up in the night

Acknowledgements

We thank Yu-Ting Huang at the Medical Library, Wanfang Medical Center, Taipei Medical University, Taiwan, who established comprehensive search strategies. We also thank Professor Ken N. Kuo who helped revising the English writing.

Authors' contributions

CW, HC, KH and CF helped with design and modification of study protocol. CW and HC searched the database. CW and HC screened data extraction and risk of bias assessment. KH and CF analyzed and interpreted the data and wrote the first draft. KH and CF helped with critical revision of the study results, and with modifications necessary for the final version to be published. All authors contributed to subsequent versions and approved the final article.

Funding

Funding for this research was provided mainly by Taipei Medical University (no. TMU106-AE1-B12, 109TMU-WFH-06) and Taiwan Ministry of Science and Technology (MOST 107–2320-B038–018-MY2).

Availability of data and materials

Not applicable.

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflicts of interests relevant to this article.

Author details

¹Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. ²Center for Nursing and Healthcare Research in Clinical Practice Application, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. ³Department of Public Health, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. ⁴Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan. ⁵Division of Plastic Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, No.111, Sec. 3, Xinglong Rd., Wenshan Dist., Taipei City 116, Taiwan, Republic of China. ⁶Evidence-based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. ⁷Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.

Received: 29 April 2020 Accepted: 24 August 2020 Published online: 14 September 2020

References

- Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003;22(2):S40–5.
- Shi T, McAllister DA, O'Brien KL, Simoes EA, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098): 946–58.
- Chou T, Chen EY, Liu YY, Wu IP, Chien MY, Hsiao HF, Lai SH. A comparison study: Treat acute bronchiolitis infants with hypertonic saline by small volume jet nebulizer and portable vibrating-mesh nebulizer. In B57. PEDIATRIC INFECTION. American Thoracic Society. 2018. pp. A3685.
- Ozdogan S, Koker O, Kose G, Yildirmak Y. The efficacy of nebulized hypertonic saline in acute bronchiolitis in hospital setting: A randomized and double blind trial. In B32. VIRAL INFECTION OF THE AIRWAY. American Thoracic Society. 2014. pp. A2740.
- Jacques J, Bouscambert-Duchamp M, Moret H, Carquin J, Brodard V, Lina B, et al. Association of respiratory picornaviruses with acute bronchiolitis in French infants. J Clin Virol. 2006;35(4):463–6.
- Rose RM, Pinkston P, O'Donnell C, Jensen WA. Viral infection of the lower respiratory tract. Clin Chest Med. 1987;8(3):405.
- Chen YJ, Lee WL, Wang CM, Chou HH. Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: an updated meta-analysis. Pediatr Neonatol. 2014; 55(6):431–8. https://doi.org/10.1016/j.pedneo.2013.09.013.
- Everard ML, Hind D, Freeman JV, Bradburn M. Hypertonic saline in acute bronchiolitis: randomised controlled trial (RCT) and economic evaluation (the SABRE study). Eur Respir J. 2014;44:3451.
- Panitch HB, Callahan JC, Schidlow DV. Bronchiolitis in children. Clin Chest Med. 1993;14(4):715–31.
- 10. Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet. 2017;389(10065):211-24.
- Wohl ME, Chernick V. State of the art: bronchiolitis. Am Rev Respir Dis. 1978; 118(4):759–81.
- 12. Brezinova V, Simpson H. Sleep apnoea in acute bronchiolitis. Arch Dis Child. 1982;57(6):467–72.
- Pratl B, Steinbrugger B, Weinhandl E, Zach MS. Effect of sleep stages on measurements of passive respiratory mechanics in infants with bronchiolitis. Pediatr Pulmonol. 1999;27(4):273–7.
- Snow A, Dayyat E, Montgomery-Downs HE, Kheirandish-Gozal L, Gozal D. Pediatric obstructive sleep apnea: a potential late consequence of respiratory syncitial virus bronchiolitis. Pediatr Pulmonol. 2009;44(12):1186–91.
- Uyan ZS, Turan I, Ay P, Cakir E, Ozturk E, Gedik AH, et al. Sleep disordered breathing and sleep quality in children with bronchiolitis obliterans. Pediatr Pulmonol. 2016;51(3):308–15.
- Flores-Gonzalez JC, Comino-Vazquez P, Jimenez-Gómez G, Rodriguez-Campoy P, Matamala-Morillo M, Garcia-Ortega R, et al. Epinephrine versus placebo in hospitalised infants with bronchiolitis treated with hypertonic saline solution. Arch Dis Child. 2014;99:A28–9. https://doi.org/10.1136/ archdischild-2014-307384.87.
- Panitch HB. Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction. Pediatr Infect Dis J. 2003;22(2):583–8.
- Oymar K, Skjerven HO, Mikalsen IB. Acute bronchiolitis in infants, a review. Scand J Trauma Resusc Emerg Med. 2014;3:22–3.
- 19. Wohl MEB, Chernick V. Treatment of acute bronchiolitis; 2003.
- Zhang L, Ferruzzi E, Bonfanti T, Auler MI, D'avila NE, Faria CS, Costa MM. Long and short-term effect of prednisolone in hospitalized infants with acute bronchiolitis. J Paediatr Child Health. 2003;39(7):548–51.
- Loza, B., Teunissen, J., Hochs, A., Vaessen-Verberne, A., Boehmer, A., Smeets, C., . . . et al. (2014). Effect of 3 and 6%hypertonic saline in viral bronchiolitis: a RCT. Eur Respir J, 44.
- Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database of Systematic Reviews. 2013;136(7):687–701.
- Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Dixon S, et al. Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review. Health Technol Assess. 2015;19(66):1–130. https://doi.org/10.3310/hta19660.

- Heikkila P, Renko M, Korppi M. Hypertonic saline inhalations in bronchiolitisa cumulative meta-analysis. Pediatr Pulmonol. 2018;53(2):233–42. https://doi. org/10.1002/ppul.23928.
- 25. Grewal S, Goldman RD. Hypertonic saline for bronchiolitis in infants. Can Fam Physician. 2015;61(6):531–3.
- Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 2014;69(12):1105–12. https://doi.org/10.1136/thoraxjnl-2014-205953.
- Flores P, Mendes AL, Neto AS. A randomized trial of nebulized 3% hypertonic saline with salbutamol in the treatment of acute bronchiolitis in hospitalized infants. Pediatr Pulmonol. 2016;51(4):418–25. https://doi.org/10. 1002/ppul.23306.
- Florin TA, Shaw KN, Kittick M, Yakscoe S, Zorc JJ. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr. 2014;168(7):664–70. https://doi.org/10.1001/ jamapediatrics.2013.5306.
- Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2017;12.
- Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H, Ibrahim K. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr. 2010;157(4):630–4.
- Angoulvant F, Bellettre X, Milcent K, Teglas JP, Claudet I, Le Guen CG, et al. Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: a randomized clinical trial. JAMA Pediatr. 2017;171(8):e171333. https://doi.org/10.1001/jamapediatrics.2017.1333.
- Anil AB, Anil M, Saglam AB, Cetin N, Bal A, Aksu N. High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis. Pediatr Pulmonol. 2010;45(1):41–7. https://doi.org/10.1002/ppul.21108.
- Grewal S, Ali S, McConnell DW, Vandermeer B, Klassen TP. A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department. Arch Pediatr Adolesc Med. 2009;163(11):1007–12. https://doi.org/10.1001/archpediatrics.2009.196.
- Hou A, Zhang X. Comparison of the therapeutic effect of different concentrations of aerosolized saline inhalation in the treatment of children with capillary bronchitis. Chin J Woman Child Health Res. 2016;3:343–5.
- Ipek IO, Yalcin EU, Sezer RG, Bozaykut A. The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline combination in moderate bronchiolitis. Pulm Pharmacol Ther. 2011;24(6): 633–7. https://doi.org/10.1016/j.pupt.2011.09.004.
- Islam KT, Mollah AH, Matin A, Begum M. Comparative efficacy of nebulized 3% hypertonic saline versus 0.9% Normal saline in children with acute bronchiolitis. Bangladesh J Child Health. 2018;42(3):130–7.
- Kanjanapradap T, Deerojanawong J, Sritippayawan S, Prapphal N. Does nebulized hypertonic saline shorten hospitalization in young children with acute viral wheezing? Pediatr Pulmonol. 2018;53(2):138–44. https://doi.org/10.1002/ppul.23924.
- Khanal A, Sharma A, Basnet S, Sharma PR, Gami FC. Nebulised hypertonic saline (3%) among children with mild to moderately severe bronchiolitis--a double blind randomized controlled trial. BMC Pediatr. 2015;15:115. https://doi.org/10.1186/s12887-015-0434-4.
- Kose S, Sehriyaroglu A, Esen F, Ozdemir A, Kardas Z, Altug U, et al. Comparing the efficacy of 7, 3 and 0.9% saline in moderate to severe bronchiolitis in infants. Balkan Med J. 2016;33(2):193–7. https://doi.org/10. 5152/balkanmedj.2016.16840.
- Kuzik BA, Al-Qadhi SA, Kent S, Flavin MP, Hopman W, Hotte S, Gander S. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr. 2007; 151(3):266–70, 270.e261. https://doi.org/10.1016/j.jpeds.2007.04.010.
- Kuzik BA, Flavin MP, Kent S, Zielinski D, Kwan CW, Adeleye A, et al. Effect of inhaled hypertonic saline on hospital admission rate in children with viral bronchiolitis: a randomized trial. Cjem. 2010;12(6):477–84.
- 42. Li G, Zhao J. Effectiveness of inhaled hypertonic saline in children with bronchiolitis. Zhonghua Er Ke Za Zhi. 2014;52(8):607–10.
- Luo Z, Fu Z, Liu E, Xu X, Fu X, Peng D, et al. Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis. Clin Microbiol Infect. 2011;17(12):1829–33. https://doi.org/10. 1111/j.1469-0691.2010.03304.x.
- Luo Z, Liu E, Luo J, Li S, Zeng F, Yang X, Fu Z. Nebulized hypertonic saline/ salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis. Pediatr Int. 2010;52(2):199–202. https://doi.org/10. 1111/j.1442-200X.2009.02941.x.

- Maheshkumar, K., Karunakara, B., Nagalli, M., & Mallikarjuna, H. (2013). Aerosolised hypertonic saline in hospitalized young children with acute bronchiolitis: a randomized controlled clinical trial J Pediatric Sci, 5.
- Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A, Priel IE. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest. 2003;123(2):481–7.
- Miraglia Del Giudice M, Saitta F, Leonardi S, Capasso M, Niglio B, Chinellato I, et al. Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchiolitis. Int J Immunopathol Pharmacol. 2012; 25(2):485–91. https://doi.org/10.1177/039463201202500218.
- Morikawa Y, Miura M, Furuhata MY, Morino S, Omori T, Otsuka M, et al. Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: a multicenter randomized controlled trial. Pediatr Pulmonol. 2018;53(3):358–65. https://doi.org/10.1002/ppul.23945.
- Ojha AR, Mathema S, Sah S, Aryal UR. A comparative study on use of 3% saline versus 0.9% saline nebulization in children with bronchiolitis. J Nepal Health Res Counc. 2014;12(26):39–43.
- Pandit S, Dhawan N, Thakur D. Utility of hypertonic saline in the management of acute bronchiolitis in infants: a randomised controlled study. Int J Clin Pediatrics. 2013;2(1):24–9.
- Ratajczyk-Pekrul K, Gonerko P, Peregud-Pogorzelski J. The clinical use of hypertonic saline/salbutamol in treatment of bronchiolitis. Pediatr Pol. 2016; 91(4):301–7. https://doi.org/10.1016/j.pepo.2016.04.006.
- Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA, Mandelberg A. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest. 2002;122(6):2015–20. https://doi.org/10.1378/chest.122.6.2015.
- Sharma BS, Gupta MK, Rafik SP. Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial. Indian Pediatr. 2013;50(8):743–7.
- Silver AH, Esteban-Cruciani N, Azzarone G, Douglas LC, Lee DS, Liewehr S, et al. 3% hypertonic saline versus Normal saline in inpatient bronchiolitis: a randomized controlled trial. Pediatrics. 2015;136(6):1036–43. https://doi.org/ 10.1542/peds.2015-1037.
- Tal G, Cesar K, Oron A, Houri S, Ballin A, Mandelberg A. Hypertonic saline/ epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience. Isr Med Assoc J. 2006;8(3):169–73.
- Teunissen J, Hochs AH, Vaessen-Verberne A, Boehmer AL, Smeets CC, Brackel H, et al. The effect of 3 and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial. Eur Respir J. 2014;44(4):913–21. https://doi.org/10.1183/09031936.00159613.
- 57. Wang S. Nursing research on the effect of high concentration saline inhalation on bronchiolitis. J Qiqihar Med College. 2014;20:3068–9.
- Wu S, Baker C, Lang ME, Schrager SM, Liley FF, Papa C, et al. Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial. JAMA Pediatr. 2014;168(7):657–63. https://doi.org/10.1001/jamapediatrics.2014.301.
- Diarmaid S, Paul M, Anne F, Kenny A, Niamh M, Michael F. The impact of a change to hospital guidelines on prescribing practices of nebulised 3% w/v 'hypertonic' saline. Arch Dis Child. 2018;103(2). https://doi.org/10.1136/ archdischild-2017-314584.51.
- 60. Gorinova Y, Simonova O, Lashkova Y, Bakradze M. Hypertonic saline in children with bronchiolitis. Eur Respir J. 2014;44.
- Koch M, Mentzel H, Ledermüller R. Inhalation therapy with hypertonic saline (3%)–A treatment option for airway disease in children? Eur Respir J. 2015; 46:PA1251.
- Auger KA, Parker MW, Huang B. New method, same answer: we do not know if hypertonic saline helps bronchiolitis. Pediatrics. 2018;142(3). https://doi.org/10.1542/peds.2018-1868.
- Chao JH, Sinert R. Is nebulized hypertonic saline solution effective for acute bronchiolitis? Ann Emerg Med. 2017;69(1):e1–2. https://doi.org/10.1016/j. annemergmed.2016.07.001.
- Overmann KM, Florin TA. Nebulised hypertonic saline may be less effective than previously reported in reducing hospital length of stay and admission rate in acute bronchiolitis. Evid Based Med. 2016;21(4):143. https://doi.org/ 10.1136/ebmed-2016-110452.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.